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ABSTRACT 
 Cocaine abuse affects millions of people with disastrous medical and societal 
consequences. Despite this, there is still no FDA-approved treatment to decrease the 
likelihood of relapse in rehabilitated addicts, and acute cocaine toxicity (overdose) is only 
symptomatically treated. Studies have demonstrated a promising potential treatment 
option with the help of the human serum enzyme butyrylcholinesterase (BChE), an 
enzyme capable of breaking down cocaine into biologically inactive side products. This 
activity of wild-type BChE, however, is relatively low. This prompted the design of 
variants of BChE which exhibit significantly improved catalytic activity against cocaine. 
Plants were used as a sustainable, scalable, affordable platform system to produce large 
amounts of human biologics such as these cocaine hydrolase variants of BChE. Using a 
tobacco relative, Nicotiana benthamiana, recombinant enzymes can be produced at 
quantities relevant to clinical use with desired kinetic properties. Next, the ability of the 
most promising plant-produced cocaine super hydrolase, pCocSH, to counter the lethal 
effects of cocaine overdose in vivo was tested. These studies revealed that this plant-
produced enzyme can protect mice from an otherwise lethal dose of cocaine. Most 
excitingly, it was found that pCocSH can rescue mice from overdose when given 
immediately after the onset of cocaine-induced seizures. These studies provide in vitro 
and in vivo proof-of-principle for a promising plant-derived biologic to be used as a 
pharmacokinetic-based treatment for cocaine addiction-related diseases such as overdose. 
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1 INTRODUCTION 
 Cocaine is one of the most widely abused recreational drugs in the United States 
and is considered one of the most reinforcing of all drugs of abuse (Mendelson and 
Mello, 1996; Substance Abuse and Mental Health Services Administration, 2013). 
Cocaine abuse is associated with a high rate of relapse and devastating personal and 
social consequences (Devlin and Henry, 2008; Substance Abuse and Mental Health 
Services Administration, 2013). In 2013, 1.5 million Americans (aged 12 and older) were 
currently using cocaine, meaning they had used the drug during the month prior to being 
interviewed (Substance Abuse and Mental Health Services Administration, 2013). 
Despite this, there is no Food and Drug Administration (FDA)-approved treatment to 
decrease the likelihood of relapse and acute intoxication (i.e. overdose) is only 
symptomatically treated (Schwartz et al., 2010; Jakkala-Saibaba et al., 2011; Arora et al., 
2013; Carreiro et al., 2014). A potential therapeutic strategy for cocaine overdose and 
preventing likelihood of relapse involves an enzyme-based approach to accelerate 
cocaine metabolism in the body. Wild type (WT) butyrylcholinesterase (BChE) is an 
enzyme that naturally hydrolyzes cocaine; however, this catalytic activity is very low. 
Computational strategies have been developed to design enzyme mutants with improved 
catalytic activity. This led to the discovery of high activity cocaine hydrolase BChE 
mutants. By testing whether plants can serve as a source for recombinant cocaine-
hydrolase variants of BChE, this study will contribute toward the development of a 
sustainable, inexpensive anti-cocaine treatment.  
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Cocaine Pharmacology and Toxicology Overview 
  Naturally occurring (-)-cocaine (benzoylmethylecgonine) is an alkaloid derived 
from the coca plant (Erythroxylum coca). Cocaine has two enantiomers: naturally 
occurring (-)-cocaine and unnatural (+)-cocaine which is biologically inactive; hereafter, 
(-)-cocaine and cocaine will be used synonymously. Similar to other plant alkaloids like 
nicotine and caffeine, cocaine acts as a natural insecticide for the coca plant to protect its 
leaves from feeding insects (Nathanson et al., 1993). When ingested by the insect, 
cocaine potentiates the transmission of a key insect neurotransmitter, octopamine, 
(similar to norepinephrine) by inhibiting octopamine reuptake, leading to cocaine-
induced toxicity (Nathanson et al., 1993; Roeder, 1999). 
  When ingested by mammals, the action of cocaine leads to a well-known 
stimulatory effect (Ciccarone, 2011). Once in the blood stream, the molecule travels 
throughout the body affecting the peripheral nervous system (PNS) and crossing the 
blood-brain-barrier and entering the central nervous system (CNS). Cocaine blocks the 
norephinephrine reuptake transporters in the PNS leading to increased norepinephrine 
concentration in the synaptic clefts which can lead to symptoms such as an increase in 
heart rate, high blood pressure (Platt et al., 2007; Ding et al., 2010). Cocaine can also 
reversibly bind to and inactivate sodium channels which affects the propagation of 
impulses along the course of the nerve and can lead to cardiac arrhythmias and local 
anesthesia (O'Leary and Hancox, 2010). The effects of cocaine such as alterations in 
blood pressure and heart rate can be seen after a single use of the drug (Gawin, 1991; 
Schwartz et al., 2010). 
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 An extremely high bolus of cocaine can cause acute cocaine toxicity (overdose) 
that can lead to major organ damage, particularly to the heart, and sudden death (Phillips 
et al., 2009; Maraj et al., 2010). There are 3 main phases associated with acute cocaine 
toxicity in humans with varying signs and symptoms as follows (not all inclusive): Phase 
I (early stimulation) involves signs of euphoria, excitation, increases respiration rate, 
elevated body temperature and increased pulse; Phase II (advanced stimulation) involves 
generalized seizures, decreased responsiveness to all stimuli, incontinence, irregular 
pulse, dyspnea (labored breathing); and Phase III (premorbid state) involves coma, loss of 
vital functions, circulatory failure, cardiac arrest and respiratory failure (Cocaine, 2012). 
Additional side effects of cocaine use include anxiety, restlessness, and paranoia (Breiter 
et al., 1997). 
  Once the drug passes the blood-brain-barrier it reaches the brain where it can 
then act on drug-reward centers of the brain. In addition to norepinephrine transporters, 
cocaine can bind to and block dopamine (Ritz et al., 1987) and serotonin (Mateo et al., 
2004) transport proteins and consequently prevent the re-uptake of the respective 
neurotransmitters (Sora et al., 2001). This consequently prolongs the presence of the 
neurotransmitter the synapses, maintaining prolonged post-synaptic activation. The 
ability of cocaine to bind to and block the function of dopamine transporters (DAT) is 
critical for the reinforcing effects of the drug (Ritz et al., 1987; Volkow et al., 1999a; 
Volkow et al., 1999b). Under normal conditions, dopamine, a neurotransmitter involved 
in reward-driven learning, is released into the synaptic cleft where it binds to postsynaptic 
dopamine receptors. After this action is complete and the post-synaptic neuron has 
received this signal, the dopamine is recycled back into the presynaptic neuron by a DAT, 
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thus extinguishing the dopamine signal. Cocaine binds to DAT blocking the function of 
this transporter, thus uptake of the dopamine is inhibited leading to an increased 
concentration of dopamine in the synapse (Seger, 2010).  
 These mechanisms contribute to the pleasurable effects of cocaine such as 
increased feelings of euphoria among other rewarding feelings, that is the primary reason 
why people take the drug in addition to feelings of increased alertness and energy. The 
most common modes by which people administer cocaine are through nasal insufflation 
(i.e. snorting), inhalation of vapor formed via sublimation, or by injection. The route of 
administration used can influence the duration of action and the reinforcing effects of the 
drug (Volkow et al., 1999b). At rewarding doses of cocaine the length of time of the 
cocaine ‘high’ can vary depending on the individual, route of administration, dose, etc. 
Depending on these factors, the duration of cocaine’s pleasurable effects (the so called 
“high”) generally ranges from about 5 – 20 minutes (Smith et al., 2001). 
 It has been shown that even a single use of cocaine can result in the down-
regulation of dopamine receptor expression and up-regulation of DATs for as long as a 
month and possibly longer (Schmitt and Reith, 2010; Seger, 2010). This leads to drug 
tolerance in which a given dose will no longer elicit the same ‘high’ due the changes 
dopaminergic signaling which can lead to cravings and drug-seeking behavior.  
 Cocaine is a highly addictive, rewarding/reinforcing drug and results in high 
incidences of relapse, and dependence is characterized largely by a psychological desire 
to use cocaine. This is somewhat different from drugs such as opiods like heroin and 
morphine that are associated with more excessive physical withdrawal effects that lead to 
a physical sense of need for the drug (Nestler, 2004; Volkow et al., 2006). 
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Metabolism of Cocaine  
 The circulatory half-life of cocaine in humans is approximately 40-90 minutes 
following an i.v. injection (Sholar et al., 1998; Turner et al., 2002) and 16 minutes in 
mice following an i.p. injection of either 10 or 25 mg/kg; and depending on dose and 
route of administration its effects can be observed in under one minute (Benuck et al., 
1987). The degradation of cocaine is accounted for via two main separate metabolic 
pathways by different enzymes in humans: BChE and liver carboxylesterases (CE)s. The 
natural enzymes BChE and human (h) liver CE-2 metabolize cocaine into 
nonpsychoactive metabolites, benzoic acid and ecgonine methyl ester, by hydrolyzing the 
benzoyl ester of cocaine, although BChE is the principle cocaine hydrolase in the serum 
(Figure 1) (Inaba et al., 1978). In primates, about 45% of administered cocaine is 
hydrolyzed by BChE, and clearance of the drug can be accelerated by the enzyme (Xie et 
al., 1999; Carmona et al., 2000; Sun et al., 2002b). A third human enzyme, liver hCE-1, 
hydrolyzes the methyl ester to yield benzoyl ecgonine and methanol (Madden and 
Powers, 1990; Larsen et al., 2002). In a minor pathway, oxidative N-demethylation of 
cocaine by liver cytochrome P450 enzymes can result in the production of a toxic 
product, norcocaine (Kloss et al., 1983; Sun et al., 2002b). In the presence of ethanol, the 
hepatic pathway produces a pharmacologically active and toxic metabolite, cocaethylene; 
and furthermore ethanol can inhibit metabolism of cocaine by CEs (Roberts et al., 1993; 
Brzezinski et al., 1994; Parker et al., 2014). Consequently, co-administration of both 
alcohol and cocaine increases the chance for an overdose reaction. 
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Figure 1. Cocaine metabolism.  
BChE and hCE-2 hydrolyze the benzoyl ester of cocaine to yield the biologically 
inactive metabolites benzoic acid and ecgonine methyl ester. hCE-1 hydrolyzes cocaine 
to yield the pharmacologically active benzoylecgonine which can produce the toxic 
metabolite, cocaethylene in the presence of ethanol. In a minor pathway accounting for 
about 5% of cocaine metabolism, cocaine can be demethylated by cytochrome P450 
enzymes in the liver to yield the toxic product norcocaine. 
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Approaches Toward a Treatment for Cocaine Addiction and Overdose 
 There are two primary strategies for the treatment of drug overdose and addiction. 
One approach, termed a “pharmacodynamics” strategy, involves developing a treatment 
that will disrupt the effect of the drug at sites of action in the body (Gorelick, 2012). An 
example of a pharmacodynamic strategy for cocaine abuse would be an agonist or 
antagonist such as dopamine transporter inhibitors or dopamine receptor antagonists to 
decrease cocaine toxicity (Zheng and Zhan, 2011). This pharmacodynamic approach is 
hard to achieve without affecting normal dopamine function because the cocaine binding 
site is also the binding site of the important neurotransmitter dopamine. It is thus very 
difficult to block the action of cocaine binding to DATs for example, without also 
affecting the ability of dopamine to bind to DATs using an antagonist (Beuming et al., 
2008; Gorelick, 2008; Huang et al., 2009a). These challenges led to the development of a 
second approach called a “pharmacokinetic” strategy. This involves acting on the drug 
molecule itself to effectively reduce the concentration of the drug at sites of action in the 
body (Gorelick, 2012). Groups have pursued this pharmacokinetic approach in 
developing treatments for cocaine overdose and addiction (Moreno and Janda, 2009; 
Zheng and Zhan, 2009; Kinsey et al., 2010; Zheng and Zhan, 2011). Progress using this 
approach will be described below. 
Cocaine-Binding Antibodies as an Anti-Cocaine Therapeutic 
 One therapeutic method using this pharmacokinetic approach involves a cocaine-
binding antibody which could be supplied via vaccine or by passive immunity (Kinsey et 
al., 2010). The vaccine is typically designed as a conjugate vaccine of a hapten such as 
succinyl norcocaine covalently attached to a carrier protein such as bovine serum albumin 
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(BSA), keyhole limpet hemocyanin, or cholera toxin B subunit. This succinyl norcocaine-
cholera vaccine is effective at eliciting antibodies (Kantak et al., 2000). By quickly 
binding tightly to the cocaine molecule, the antibody prevents the drug from crossing the 
blood-brain barrier and thus prevents the rewarding effects of the drug (Kinsey et al., 
2010). However, in published clinical trials of cocaine conjugate vaccines (Martell et al., 
2009), only about a third of the immunized subjects produced sufficient levels of 
antibody to effectively reduce uptake of the drug by the central nervous system. For a 
discussion on the status and progress of this cocaine vaccine strategy see: (Orson et al., 
2014) 
 Although the active immunization approach does indeed elicit an antibody 
response, it may take several months after receiving the vaccine to have a primed 
immune system. Furthermore, antibody levels are expected to be easily overwhelmed 
especially in the case of persistent abusive users who take more than one large dose of the 
drug in a short amount of time. Since the antibody binds the drug in a stoichiometric 1:1 
ratio, high antibody levels will be necessary. To avoid these stoichiometric limitations of 
traditional antibodies, catalytic cocaine antibodies have been developed capable of not 
only binding cocaine, but hydrolyzing the drug as well and as such may be considered 
artificial enzymes (Cashman, 1997; Mets et al., 1998; Pan et al., 2008). Administration of 
these catalytic antibodies was shown to rapidly lower the concentration of cocaine in 
plasma in mice with a dose of 100mg antibody per kg bodyweight; however, frequent 
administration will be necessary in order to sustain the high levels of antibody in the 
circulation (Briscoe et al., 2001). The catalytic antibodies may conceivably have a lower 
affinity for cocaine compared to their non-catalytic counterparts that bind to cocaine 
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extremely quickly, efficiently, and tightly (Mets et al., 1998; Briscoe et al., 2001; Kinsey 
et al., 2010). Even with improvements, the catalytic efficiency of the most advanced 
catalytic antibody, mAb 15A10, is so low (KM = 220 µM, kCAT = 2.3 min-1) that an 
extremely high dose (15-50 mg/kg) would be necessary for effective treatment and 
research has transitioned to another catalytic approach based on enzymes which naturally 
hydrolyze cocaine (Cooper et al., 2006; Pan et al., 2008).  
Enzyme-Based Approach to an Anti-Cocaine Therapeutic 
 Various enzymes have been investigated to serve in this therapeutic enzyme-
based approach to treat cocaine-addiction related diseases. There are two enzymes that 
are obvious targets that have a native activity hydrolyzing cocaine into the biologically 
inactive ecgonine methyl ester and benzoic acid products. These two enzymes are the 
bacterial cocaine esterase (CocE) and the human serum enzyme BChE. Cocaine 
hydrolases based on both of these enzymes are currently regarded as promising potential 
therapeutics capable of highly efficient cocaine metabolism. 
 The idea of isolating an enzyme from the environment that is able to naturally 
metabolize cocaine was the basis for utilizing one of those enzymes, CocE. There are 
Rhodococcal strains of bacteria that live in the soil around the coca plant (E. coca) which 
metabolize cocaine as their only carbon source (Britt et al., 1992; Bresler et al., 2000; 
Cooper et al., 2006). The gene encoding for CocE was cloned from a strain of 
Rhodococcus (strain MB1) in the early 2000’s (Bresler et al., 2000). Since then great 
strides have been made toward developing this esterase for use as a potential treatment 
for cocaine addiction and overdose (Gao et al., 2009; Huang et al., 2011; Collins et al., 
2012; Fang et al., 2014a; Howell et al., 2014). A drawback of this system using a 
  
10 
bacterial enzyme in a human, aside from safety concerns inherent to the bacterial source, 
involves elicitation of an immune response resulting in reduced CocE effectiveness (Ko 
et al., 2007) as well as a lack of circulatory stability (Cooper et al., 2006). However, 
improvements have been made to increase thermostability of the enzyme (Cooper et al., 
2006; Ko et al., 2007; Gao et al., 2009; Ko et al., 2009; Brim et al., 2010; Collins et al., 
2011; Brim et al., 2012; Collins et al., 2012; Connors and Hoffman, 2013). 
 The other major enzyme of interest targeted for development as an anti-cocaine 
therapy is the human serum enzyme BChE. As discussed above, BChE is an enzyme that 
catalyzes the normal clearance of cocaine in the body. Although much pioneering work 
was done in the late seventies concerning studying the ability of BChE to hydrolyze 
cocaine (Stewart et al., 1977; Inaba et al., 1978; Stewart et al., 1979; Gorelick, 1997), it 
was not until the late 1990’s that it was first proposed that this enzyme could be utilized 
as a treatment strategy for cocaine abuse. 
 Initially, the wild-type form of BChE was purified from plasma or derived from 
other sources, and tested for its ability to rescue for cocaine overdose (Mattes et al., 
1997). However, this native BChE only achieves the hydrolysis of cocaine very slowly 
and thus this endogenous enzyme was not found to be effective enough to be used as a 
treatment. Despite this low catalytic activity, the enzyme does have the advantage of 
naturally being found in human serum, unlike the bacterial derived CocE. Still it was 
clear that the WT form of BChE is too sluggish to provide the bioscavenging properties 
necessary for effective clinical use. The cloning of the gene encoding BChE in 1988, the 
elucidation of the 3D structures of AChE and BChE, and various recombinant DNA 
methods for over production of the enzyme, opened up the possibilities for rational 
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redesign of human BChE as an efficient cocaine hydrolase. We will now discuss these 
developments in our understanding of the structure and function of BChE before 
returning to its anticocaine activity and its utilization for detoxification. 
BChE Structure  
 Human BChE (hBChE) from plasma is a soluble, glycosylated, globular protein 
(Darvesh et al., 2003). The catalytic activity of BChE takes place at the active site of the 
enzyme located at the bottom of a 20-Å deep gorge (Nicolet et al., 2003). A second 
substrate binding site, the peripheral anionic site (PAS), is located at the top of the gorge. 
This relatively low-affinity site functions to attract positively charged substrates to the 
gorge. The PAS is also responsible for the profound substrate-associated allosteric effect, 
i.e. substrate activation, that is characteristic of BChE (Masson et al., 2001).  
 Native plasma hBChE is found in the serum at approximately 3.5-5 mg/L 
(Grunwald et al., 1997) and consists of 98% 340 kDa tetramers. Plasma-derived enzyme 
administered to humans has a half-life of 11-14 days (Ostergaard et al., 1988; Ngamelue 
et al., 2007). Each tetramer is comprised of the pairing of two dimers which consist of 
two monomers joined by a disulfide bond formed between the cysteine in position 571 
(Lockridge et al., 1987a). Each of the monomers are 574-amino acid long and contain 
internal disulfide bonds as well as nine N-linked glycosylation sites (Lockridge et al., 
1987b). Outside of the bloodstream, BChE is found in neuromuscular junctions and in 
central nervous system synapses in water-insoluble forms. BChE tetramers can be found 
at the basal lamina of the neuromuscular junction anchored by collagen Q (ColQ), a 
specialized variant of collagen that is part of the extracellular matrix. The tryptophan-rich 
C-terminal domain of BChE (the so-called tryptophan amphiphilic tetramerization 
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“WAT” domain) interacts with the proline rich attachment domain (PRAD) of ColQ. 
Within the central nervous system, BChE tetramers are anchored to neural cell 
membranes via the integral membrane protein PRiMA (proline rich membrane anchor) 
through its PRAD (Figure 2) (Krejci et al., 1997; Feng et al., 1999; Perrier et al., 2002; 
Darvesh et al., 2003). The soluble tetrameric form present in the serum has been shown to 
associate with proline-rich peptides derived from lamellipodin (Li et al., 2008b). BChE is 
found in tissues such as the liver and lungs as well. 
 The final 40 amino acids of the C-terminus of BChE comprises the WAT domain 
of the protein that facilitates the noncovalent association of monomers to form dimers 
and tetramers in the presence of proline-rich peptides (Blong et al., 1997; Altamirano and 
Lockridge, 1999b, a; Li et al., 2008b). Deletion of this domain exclusively results in 
monomer formation, although it should be noted that this truncated form of BChE has 
been found to retain its catalytic activity (Blong et al., 1997). Due to the current lack of 
X-ray crystal structure of the tetrameric form of each BChE subunit’s association with 
proline-rich peptides, molecular modeling is currently being studied to gain a better 
understanding of this interaction (Pan et al., 2009). This will be discussed further in 
Chapter 4. 
  
  
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2. Oligomeric forms of BChE.  
1°, 2°, and 4°, represent the respective soluble monomer, dimer and tetramer 
forms of BChE In addition to serum, the tetrameric form of BChE can be found 
anchored to membranes through its interaction with the proline-rich attachment 
domains (PRAD)s of the proline-rich membrane anchor PRiMA (red) and of the 
collagen tail, ColQ (yellow). Adapted from (Darvesh et al., 2003). 
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BChE Function  
 Humans possess two cholinesterases, acetylcholinesterase (EC 3.1.1.7, AChE) 
and BChE (EC 3.1.1.8). AChE plays a major role in cholinergic transmission; however, 
the physiological role of BChE is not yet fully understood. A direct cholinergic role for 
BChE was suggested by the fact that AChE-knockout mice, expected to be embryonic 
lethal, developed to term (Li et al., 2000; Xie et al., 2000; Lockridge et al., 2011). In 
these mice, synaptic BChE compensates, at least partially, for the loss of AChE. Along 
these lines BChE is now thought to play a role in the progression of Alzheimer’s Disease 
as BChE activity has been observed to increase progressively in patients with the disease 
not as a consequence of anti-cholinesterase drugs (Perry et al., 1978; Arendt et al., 1992; 
Greig et al., 2002; Giacobini, 2003; Mufson et al., 2008). 
  Interestingly, humans who lack BChE activity are healthy (Primo-Parmo et al., 
1996). Similarly, BChE knock-out mice show no clear phenotypes under normal 
conditions (Li et al., 2006; Li et al., 2008a). However, such mice are more susceptible to 
the toxic effects of a number of xenobiotic substances such as organophosphate (OP) 
nerve agents, pesticides, and plant alkaloids (McGehee et al., 2000; Taylor, 2001; 
Decker, 2005; Khan et al., 2005; Loizzo et al., 2008). This suggests a role of BChE in 
scavenging OP pesticides and nerve agents and thus is able to help protect the 
neurologically important AChE. 
 People who either produce the atypical (A) variant form (negatively charged 
asparagine at the peripheral anionic site is mutated to glycine) or a more severely 
deficient silent (S) form of BChE typically do not notice any deleterious effects from not 
having the normal form of BChE, but rather exhibit a normal phenotype in the absence of 
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anticholinesterases (McGuire et al., 1989; Soliday et al., 2010). The protective role of 
BChE typically becomes most apparent in response to neuromuscular targeting drugs and 
compounds. Humans who lack BChE activity are normally asymptomatic and healthy 
unless exposed to neuromuscular blocking agents. For example, people with the S form 
of BChE can be more vulnerable to poisoning by organophospherous pesticides as was 
observed with farmers expressing the S form of BChE (Prody et al., 1989). Another 
example is seen with administration of succinylcholine, a drug commonly used as muscle 
relaxant used to facilitate tracheal intubations in the medical arena (Liddell et al., 1962; 
Primo-Parmo et al., 1996; Levano et al., 2005; Geyer et al., 2013). Patients with BChE 
deficiency can experience prolonged respiratory paralysis necessitating further 
mechanical ventilation until neuromuscular function can be regained (Viby-Mogensen 
and Hanel, 1978; Soliday et al., 2010). In addition to BChE hydrolyzing succinylcholine, 
BChE can also hydrolyze various other compounds including succinylcholine’s name-
sake substrate, butyrylcholine (BCh), ACh, ghrelin, acetylsalicylic acid (aspirin) and 
cocaine (Masson et al., 1998; Ashani, 2000; Koetzner and Woods, 2002; Mesulam et al., 
2002; Reid et al., 2013; Chen et al., 2015).  
Redesign of Human BChE as a Cocaine Hydrolase 
 In 1999, a group began to attempt to increase the catalytic efficiency of the BChE 
enzyme through testing many mutants involving changing amino acids lining the active 
site gorge to allow the cocaine molecule to more easily fit into the active site. This led to 
the discovery that an A328Y mutant of human BChE is four fold more efficient than WT 
BChE (Xie et al., 1999). Groups have been working toward further improving the 
catalytic efficiency of BChE, which has led to the development of numerous mutant 
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variants such as (A199S/S287G/A328W/Y332G) and 
(A199S/F227A/S287G/A328W/Y332G) which yield an efficiency that is now over 1000-
fold improved over WT BChE (Sun et al., 2002a; Sun et al., 2002b; Pan et al., 2005; 
Brimijoin et al., 2008; Zheng et al., 2008; Yang et al., 2010; Carroll et al., 2011; Xue et 
al., 2011; Anker et al., 2012; Xue et al., 2013a; Xue et al., 2013b; Zheng et al., 2014) 
(Figure 3). These enzymes have been shown to be so efficient that they can even result in 
lowering cocaine concentrations at target sites in the brain while they themselves are 
unable to across the blood brain barrier (Brimijoin et al., 2008; Gao and Brimijoin, 2009). 
These advances have contributed toward the development of a BChE-based anti-cocaine 
therapeutic agent. 
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Figure 3. Model of WT hBChE monomer.  
Amino acids which have been mutated to create the cocaine super 
hydrolase variant (A199S/F227A/S287G/A328W/Y332G) are 
highlighted by colors with arrows. 
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 Since that time, many studies have been conducted to determine not only if these 
newly designed, more efficient enzymes could blunt the effects of cocaine toxicity, but 
also if cocaine-seeking behavior could be reduced as well. For example, a telling study 
published in 2008 described rats given the highly efficient BChE-derived cocaine 
hydrolase before cocaine administration showed protection from signs of cocaine 
toxicity, while exhibiting rescue from cocaine-induced seizures when administering the 
BChE quickly following observation of the convulsions (Brimijoin et al., 2008). These 
mutants derived from mammalian systems have been shown to fully protect mice and rats 
from respective lethal doses of cocaine (180 mg/kg and 100 mg/kg) (Brimijoin et al., 
2008; Zheng et al., 2008; Xue et al., 2011). Furthermore, the BChE cocaine hydrolase 
was shown to be effective at blocking cocaine-primed reinstatement in rats trained to 
self-administer the drug (Brimijoin et al., 2008; Zlebnik et al., 2014). Although progress 
has been made toward developing these highly efficient cocaine hydrolases, a cost-
effective, sustainable, pragmatic source of these recombinant enzymes has yet to be 
established.  
Gene Therapy for the Delivery of Cocaine Hydrolases  
 Because BChE-based cocaine hydrolases are products of genetic engineering, 
there is a need to develop effective methods for production and delivery of these 
sophisticated biologics. One approach combines in vivo production and delivery of the 
recombinant enzyme using the toolbox of gene therapy. 
 Gene therapy has been researched as a way to produce BChE-based cocaine 
hydrolases in vivo by delivering the gene to the person via an adenoviral transfer vector 
to produce the therapeutic in the body’s own cells (Parikh et al., 2011; Anker et al., 2012; 
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Brimijoin and Gao, 2012; Gao et al., 2013; Geng et al., 2013; Murthy et al., 2014a; 
Murthy et al., 2014b; Zlebnik et al., 2014). This method has already been investigated 
with the cocaine hydrolase variants of BChE yielding high (50,000 fold improved) levels 
of plasma cocaine hydrolase activity (Gao et al., 2005; Gao and Brimijoin, 2005; 
Brimijoin and Gao, 2012). This response, however, was not prolonged, and returned to 
pretreatment levels within 10 days with indication of a neutralizing antibody response 
against BChE (Brimijoin and Gao, 2012). Another vector, the helper-dependent 
adenoviral vector was also used in an attempt to improve long-term delivery (Morral et 
al., 1999; Parks et al., 1999; Gao and Brimijoin, 2009). Long term expression was 
sustained using this system and plasma cocaine hydrolase activity still rose about 25,000 
fold (to about 1.1 mg BChE/ mL plasma), although that is about half as effective as the 
original adenoviral vector (Gao and Brimijoin, 2009). Work using this helper-dependent 
adenoviral vector-mediated approach also reduced the locomotor-activating effects of 
cocaine and prevented reinstatement of cocaine-seeking behavior in rats for up to 6 
months and can yield long-lasting levels of the BChE-based cocaine hydrolase able to 
diminish long-term cocaine intake (Geng et al., 2013; Murthy et al., 2014a; Zlebnik et al., 
2014). Although high levels of the cocaine hydrolase were generated using the gene 
therapy approach, problems can arise from the gene transfer vector system itself. If a 
patient has already been exposed to a virus of the same serotype in their day-to-day lives, 
then active immunity will prevent this entire system from working. For similar reasons, 
re-administration of the vector used for initial gene transfer is impossible (Brimijoin et 
al., 2013). Rehabilitated cocaine addicts may be at risk of relapse for years and the 
inability to re-administer this system would make this approach completely ineffective if 
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cocaine hydrolase activity were to decline while the patient was still at risk of relapse. 
The nature of the issues surrounding gene therapy and its feasibility of application in 
patients struggling with drug addiction should be considered. 
Sources of BChE and BChE Variants 
  To be an effective treatment for the millions of people affected by drug addiction 
and overdose, the enzyme-based therapy necessitates large quantities of the protein that 
are not prohibitively expensive. In fact, the main criticism of the BChE-based cocaine 
hydrolase approach is the potential high cost associated with producing the recombinant 
protein and cost-efficiency should be a primary concern when deciding on an expression 
system (Connors and Hoffman, 2013). Current and previously published sources of 
BChE include outdated human plasma (Lockridge et al., 2006; Sun et al., 2013) and 
recombinant systems including mammalian cells (Ilyushin et al., 2013; Xue et al., 2013a), 
insect cells (Brazzolotto et al., 2012), silkworm (Wei et al., 2000; Li et al., 2010), 
transgenic goat milk (Huang et al., 2007; Baldassarre et al., 2008; Huang et al., 2008; 
Baldassarre et al., 2011) and plants (Geyer et al., 2010a; Geyer et al., 2010b; Schneider et 
al., 2014a). For a thorough recent review on human BChE please see the 2015 review by 
Oksana Lockridge in Pharmacology and Therapeutics and references therein (Lockridge, 
2015).  
 Recombinant highly-efficient cocaine hydrolase variants of BChE 
(A199S/S287G/A328W/Y332G and A199S/F227A/S287G/A328W/Y332G) have only 
been produced thus far in mammalian cell culture, however this expression system can be 
difficult to scale up, expensive, and prions and animal viruses have the potential to 
contaminate the recombinant product and cause safety concern (Fischer et al., 2004). 
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Although these are drawbacks to consider, these cocaine hydrolase variants have been 
successfully produced and purified to over 98% purity from Chinese Hamster Ovary 
(CHO) cells stably transfected with the gene (Xie et al., 1999; Duysen et al., 2002; Sun et 
al., 2002; Gao et al., 2008) and from human embryonic kidney (HEK) cells (Xie et al., 
1999; Duysen et al., 2002; Sun et al., 2002a; Gao et al., 2008; Zheng et al., 2008; Yang et 
al., 2010; Xue et al., 2011). Although the enzyme has been purified to near homogeneity, 
initial expression levels using the mammalian system and yields throughout the 
purification process remain largely unpublished for the BChE mutants. Expression levels 
in CHO-K1 cells was reported in 2002 to range from 1-5 mg enzyme per liter of culture 
medium (Duysen et al., 2002) and in 2011 expression in HEK 293FT cells ranged from 
4-10 mg enzyme per liter culture (Xue et al., 2011). BChE produced in these recombinant 
mammalian systems is primarily produced in the monomeric form unless tetramerization 
is induced with a supply of proline-rich peptides (this will be discussed in more detail in 
Chapter 4). 
 A plant-based recombinant protein production system has the advantage of low 
production costs as well as ease of scalability (Daniell et al., 2009; Nagels et al., 2012; 
Chen et al., 2014; Sabalza et al., 2014; Tuse et al., 2014). As an example, large 
bioreactors of mammalian systems can be replaced with greenhouses or fields for lower 
facility-associated production cost and ease of scalability (Daniell et al., 2001; Daniell et 
al., 2009); although, it should be noted that cost comparison of therapeutic protein 
production in different systems is far more complex than this one example. Unlike 
bacterial and yeast-based expression systems, plant-expressed biopharmaceuticals can 
undergo complex folding and glycosylation when targeted to the endoplasmic reticulum 
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(ER). Although mammalian and plant glycosylation patterns are different, exciting 
strategies have been developed to ‘humanize’ the glycosylation pathway in plants 
(Karbiener, 2005; Castilho et al., 2010; Castilho et al., 2011; Castilho and Steinkellner, 
2012; Schneider et al., 2014a; Schneider et al., 2014b). Throughout the last decade the 
Mor laboratory has demonstrated the successful expression, purification and 
characterization of WT BChE and variants thereof in a plant-based expression system 
(Geyer et al., 2008; Geyer et al., 2010a; Geyer et al., 2010b; Geyer et al., 2013; Larrimore 
et al., 2013). 
Dissertation Overview 
 This dissertation will discuss the use of a plant-based expression system for the 
production of the most successful cocaine super hydrolase (“pCocSH”, 
A199S/F227A/S287G/A328W/Y332G), as well as several other variants of interest 
designed for enhanced cocaine hydrolysis. The first goal of expressing variants of BChE 
designed for enhanced cocaine hydrolysis in plants is discussed in Chapter 2. In Chapter 
3, the plant-derived proteins are characterized to determine their kinetic parameters and 
usefulness as a possible multivalent therapeutic. Next the oligomeric form of the plant-
derived enzyme is studied and production of a form known to have increased circulatory 
stability is established which is discussed in Chapter 4. Once it was established that 
plants can serve as a source of these enzymes at quantities relevant to clinical use with 
kinetic properties similar to mammalian-derived counterparts, their ability to function in 
vivo was evaluated. To this effect, two animal studies are discussed in Chapter 5 that 
investigated the ability of pCocSH to protect and rescue animals from cocaine-induced 
toxicity (overdose).   
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2 EXPRESSION OF BCHE-BASED COCAINE HYDROLASES  
IN NICOTIANA BENTHAMIANA 
 
Abstract 
 Variants of the human enzyme BChE designed for enhanced cocaine hydrolysis 
are being pursued as a treatment for cocaine addiction-related diseases such as overdose 
and relapse. This prompted the investigation of using plants to produce these recombinant 
glycosylated enzymes. Plants are a promising expression system because they are capable 
of producing large amounts of post-translationally modified foreign proteins, and are safe 
with no concerns regarding human pathogens. Additionally, seeds of stable transgenic 
plants can be easily preserved for long-term storage and the platform can be rapidly 
scaled up. The use of both stable transgenic and transient expression systems was used to 
test for production of BChE variants in Nicotiana benthamiana. It was determined that 
variants of interest could be expressed by both a transient and transgenic expression 
system. We have demonstrated proof-of-principle that plants can express mutants of 
BChE designed for enhanced cocaine hydrolysis in N. benthamiana. 
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Introduction 
 Several groups have created site-directed mutant variants of butyrylcholinesterase 
(BChE) to improve catalytic efficiency against (-)-cocaine (Sun et al., 2002a; Gao and 
Brimijoin, 2004; Brimijoin et al., 2008; Zheng et al., 2008; Yang et al., 2010; Xue et al., 
2011). These mutants of human BChE have been recognized as promising candidates for 
therapeutic enzymes for anti-cocaine medications (Zheng and Zhan, 2011). Current 
expression strategies for producing clinically relevant quantities of these therapeutic 
recombinant enzymes, however, are lacking. Currently, the only expression system being 
used to produce high-activity cocaine hydrolase variants of BChE are mammalian cell-
based expression platforms. Chinese hamster ovary (CHO) cells (Brimijoin et al., 2008; 
Xue et al., 2013a; Fang et al., 2014b) and human embryonic kidney (HEK) cell lines 
(Yang et al., 2010; Xue et al., 2013a; Zhan et al., 2014) are the two primary cell types 
used for recombinant protein production. Of these cell lines expression levels have been 
reported from the stable CHO lines reaching approximately 10 mg/L of culture of cocaine 
hydrolase variants of BChE (Xue et al., 2013a). In addition to not achieving high 
accumulation levels of these variants of BChE engineered for enhanced cocaine 
hydrolysis, pharmaceutical protein production in mammalian cells raises concern of 
pathogen contamination and these systems have high cost associated with scale up.  
 The use of plant biotechnology to produce pharmaceuticals (pharming) is a 
promising means to produce therapeutic human biologics such as these high-activity 
cocaine hydrolase variants, while being low cost and easily scalable. This rapidly 
growing plant-based bioprocessing platform involves using the cellular machinery of 
plants to produce and accumulate complex foreign protein products such as biologics and 
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vaccines in a form that will maintain desired biological functions. Plant biotechnology 
offers a suite of promising solutions for the scalable and cost-effective production of safe 
and efficacious biologics, as was with the recent FDA approval of the first plant-derived 
biologic for enzyme-replacement therapy of Gaucher's Disease and with the recent 
experimental plant-derived Ebola treatment, ZMapp (Zimran et al., 2011; Qiu et al., 
2014). This led us to investigate if plants could be used as an efficient source of high-
activity mutants of BChE designed for enhanced cocaine hydrolysis at quantities relevant 
to clinical use with desired catalytic properties. 
 Over the past decade the Mor lab at Arizona State University has demonstrated 
successful large-scale production of wild type (WT) BChE, along with dozens of mutant 
variants either in stably-transformed transgenic Nicotiana benthamiana plants or in WT 
plants using a virus-assisted transient expression system which exploits plant viral 
vectors that have been deconstructed for the rapid, industrial-scale expression of foreign 
proteins (Geyer et al., 2008; Geyer et al., 2010a; Geyer et al., 2010b). N. benthamiana 
has been an ideal expression host for these proteins due to its large leaf biomass, ease of 
infection by plant viruses used for transfection and is ideal for downstream 
manufacturing as it is not a food crop. Recombinant proteins can be expressed in N. 
benthamiana using traditional Agrobacterium tumefaciens-mediated transformation 
strategies as well as transient expression strategies utilizing plant virus expression 
vectors. BChE has successfully been expressed in N. benthaminana using both of these 
strategies previously, which led to the decision to further investigate this plant-based 
expression system for the production of variants of BChE designed for enhanced cocaine 
hydrolysis. The first engineered low-activity cocaine-hydrolyzing variant of BChE called 
  
26 
Variant 1 (A328W/Y332A) designed in 2002 (Sun et al., 2002a) was first reported to be 
successfully stably expressed in plants by the Mor lab, however it was being investigated 
as a potential nerve agent bioscavenger and the ability to hydrolyze cocaine and protein 
accumulation levels were not reported in that study (Geyer et al., 2008). Since this time, 
computational design has led to the discovery of a plethora of high-activity BChE 
mutants, many being more than 1000 fold more efficient at breaking down cocaine that 
WT BChE (Brimijoin and Gao, 2012). Although many extremely promising candidates 
are constantly being designed, the most efficient variant, Variant 4 aka pCocSH 
(A199S/F227A/S287G/A328W/Y332G) is of particular interest (Zheng et al., 2008; Xue 
et al., 2013a). Several other variants of interest were also explored during this study and 
included in discussions below (Table 1).  
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Table 1. Cocaine hydrolase variants of BChE. 
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  In order to express these variants of BChE in plants, two expression strategies 
were pursued in tandem. First, transgenic plants that stably express the proteins of 
interest through subsequent generations were created using Agrobacterium-mediated 
stable transformation as previously described (Geyer et al., 2005; Evron et al., 2007; 
Geyer et al., 2007; Geyer et al., 2008; Geyer et al., 2010a; Geyer et al., 2010b; Geyer et 
al., 2013). Once the genes are introduced into the host genome, resulting explants are 
then grown on selective growth media to select for transformed cells, that grow as non-
differentiated cell masses called transgenic calli. Formation of stem and root structures 
are induced by addition of synthetic cytokinin and a synthetic hormone in the auxin 
family. Regenerated whole plants confirmed to express the protein of interest are then 
allowed to mature to produce seeds which also contain the transformed gene. These seeds 
can then serve as the source of future generations of plants which will stably inherit the 
gene of interest (Gelvin, 2003).The gametes of such plants will contain the transformed 
gene of interest, the gene of interest will be stably inherited in future generations, 
allowing for protein expression in these generations without the need for successive 
transformations. As this process can take several months, concurrently a more rapid, 
although transient, virus-based expression system was also pursued. 
 Agrobacteria-mediated transient expression utilizes viral vectors that are 
transformed into the bacteria. The viral vectors used in the studies mentioned in this body 
of work are based on the Magnifection system of a deconstructed tobacco mosaic virus 
(TMV) (Marillonnet et al., 2004; Gleba et al., 2005) as well bean yellow dwarf virus 
(BeYDV) of the Geminiviridae (also referred to as Geminivirus or Gemini throughout) 
(Mor et al., 2003) which will be discussed in more detail in Chapter 4. Magnifection, 
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colloquially known as the ICON system, utilizes a deconstructed TMV-based vector that 
has a deletion of the TMV coat protein. This deletion, in a sense, attenuates the virus, still 
allowing it to move from cell to cell with the use of the movement protein (MP) but no 
longer able to exhibit systemic infection throughout the entire plant or transmission to 
other plants, aiding in containment of the virus which is important from a regulatory 
point of view. One can exploit the natural tendency of Agrobacteria to deliver portions of 
DNA between transfer-DNA (T-DNA) sequences to the plant nucleus. These sequences 
are included in each ICON module. Rather than utilizing a single vector for transient 
expression, ICON utilizes three different Agrobacteria cultures to deliver three different 
modules of the ICON system. The first plasmid, called the 5’ module, contains (in this 
study) the barley-α-amylase endoplasmic reticulum (ER)-targeting signal peptide (SP), 
though this system allows for the flexibility of choosing between several subcellular 
targeting modules if so desired. The 3’ module contains the gene of interest and the 
integrase module contains the Streptomyces phage PhiC31 integrase which will 
recombine the 5’ and 3’ module at PhiC31 integrase recombination sites and in this way 
the components will be assembled inside of the plant cell nucleus. The three A. 
tumefaciens cultures containing the 5’, 3’ and integrase modules are grown individually 
to mid-log phase then prepared in an infiltration buffer and mixed in equal concentration 
ratios then delivered to the intercellular space in the leaves of the plant either by 
physically nicking the leaf and injecting the bacteria solution with a needleless syringe, or 
by using a vacuum chamber in which the plant leaves are entirely submerged, the air is 
removed and when the vacuum is released, the bacteria enters the intercellular space. 
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 Using this expression system, the glycosylated protein, BChE, is targeted for 
secretion by addition of an ER-targeting SP. For stable expression of BChE, the 
endogenous SP of human plasma-derived BChE is used and for transiently expressed 
BChE the barley-α-amylase SP is used- both target the protein to the ER. Recombinant 
proteins expressed in plants typically contain complex-type N-glycans with ß-1,2-xylose 
and core α-1,3-fucose residues (De Meyer and Depicker, 2014). Because plant-specific 
glycans have the potential to be immunogenic, significant efforts went into the 
development of glyco-engineered plants that have humanized glycosylation pathways 
(Castilho et al., 2010; Castilho and Steinkellner, 2012; Schneider et al., 2014a; Schneider 
et al., 2014b). Alternatively, glycoproteins can be retained in the ER by adding a C-
terminal KDEL-tag to facilitate retrograde trafficking from the cis-Golgi back to ER (De 
Meyer and Depicker, 2014). The addition of the C-terminal KDEL sequence can also 
have the additional benefit of enhanced protein accumulation levels, presumably because 
the ER is a center for secretory protein folding and folding machinery, and this 
accumulation was indeed observed in the previously described transgenic plants 
expressing BChE (Fiedler et al., 1997; Geyer et al., 2007). For these reasons, the addition 
of a C-terminal SEKDEL sequence was sometimes incorporated into the study of the 
plant expression of the cocaine hydrolase variants of BChE. 
 Transient TMV-based expression was utilized for expression of Variants 2 
(F227A/S287G/A328W/Y332A), 3 (A199S/S287G/A328W/Y332G), 4 
(A199S/F227A/S287G/A328W/Y332G) and 5 (F227A/S287G/A328W/Y332G), while 
stable transgenic expression was only utilized for the most auspicious mutant, Variant 4. 
This variant is the most promising plant-derived cocaine super hydrolase and thus will 
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also be designated colloquially as pCocSH. By applying the strategies described here, I 
demonstrate proof-of-principle that plants can be used as a source to express BChE 
variants designed for enhanced cocaine hydrolase activity at quantities relevant to clinical 
use. 
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Materials and Methods 
Construction of Expression Vectors for Transient and Stable Protein Expression 
 The WT human BChE (WT hBChE) gene has previously been optimized for 
expression in dicotyledonous plants by using preferred codons and eliminating cryptic 
sequences such as RNA-destabilizing sequences, spurious polyadenalation signals, and 
unwanted splicing signals (Geyer et al., 2010b). This plant-optimized BChE (pBChE) 
gene was used as the template for all of the downstream cloning for this study (GenBank 
accession no. GQ903330.1). The pBChE with C-terminal Histidine-tag (6xHis), used for 
purification purposes, was used as a template for introduction of site-directed mutations 
(QuickChange kit, Stratagene) using mutagenic primers (Table 2) to create the following 
site-directed mutations: F227A/S287G/A328W/Y332A (Variant 2), 
A199S/S287G/A328W/Y332G (Variant 3) (Yang et al., 2010), 
A199S/F227A/S287G/A328W/Y332G (Variant 4) (Zheng et al., 2008), and 
F227A/S287G/A328W/Y332G (Variant 5) which were all verified by DNA sequencing. 
Variant 1 (A328W/Y332A) was previously expressed in plants but was not investigated 
in this study (Geyer et al., 2008). High fidelity PCR was used to remove the C-terminal 
His tag or add C-terminal SEKDEL ER retention signal to Variant 4 (Figure 4). Gene-
flanking 5’ NcoI and 3’ SacI restriction sites were used to clone the variant pBChE genes 
into the deconstructed tobacco mosaic virus (TMV)-based plant expression vector (Figure 
5). The addition of the 5’ NcoI site for cloning purposes necessitates an insertion of a 
glycine residue immediately following the initiatory methionine. These constructs were 
to be used in Agrobacterium-mediated transient expression in N. benthamiana (Figure 6).  
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 To generate stable transgenic plant lines expressing the 
(A199S/F227A/S287G/A328W/Y332G) pBChE gene with or without C-terminal 
SEKDEL, the NcoI-SacI fragments encompassing the coding regions of pCocSH were 
cloned into an expression cassette consisting of the Cauliflower mosaic virus 35S 
promoter (35S CaMV), the 5’ untranslated region (UTR) of tobacco etch virus, and 3'-
UTR and vegetable storage protein (VSP) terminator of soybean’s vspB gene. This 
cassette, flanked by HindIII and EcoRI restriction sites, was cloned into the pGPTV-Kan 
plant expression vector to yield pTM 835 and pTM 904 (Figure 4).  
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Figure 4. T-DNA and expression cassettes for the expression of pBChE 
variants in N. benthamiana.  
A. T-DNA constructs of pCocSH with C-terminal 6x histidine tag (top), 
ER-retention signal SEKDEL (middle) or no C-terminal modification 
(bottom) in the 3’ module of the MagnICON system. The purple triangle 
represents AttB – PhiC31 integrase recombination site, I - intron, 3’ NTR 
– 3’ non-translated region, nos – nopaline synthase terminator. Yellow 
stars indicate relative positions of the amino acid mutations. 
B. T-DNA constructs of pCocSH in pGPTV-Kan with (top) or without 
(bottom) C-terminal SEKDEL signal for creation of stable transgenic plant 
lines. 35S – cauliflower mosaic virus 35S promoter, TEV - tobacco etch 
virus 5’ untranslated region, SP – signal peptide endogenous to WT 
hBChE, VSP - polyadenylation signal of soybean vegetative storage 
protein gene. The scale bar for A and B is located at the bottom of the 
figure. 
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Table 2. Oligonucleotides used to create mutations in pBChE DNA 
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Figure 5. Representations of T-DNA modules used in MagnICON expression.  
5’ module (top), 3’ module (middle) and Integrase module (bottom). Act2 - Arabidopsis 
Actin 2 promoter, RdRp - RNA-dependent RNA polymerase, MP - movement protein, 
SP a - barley α-amylase apoplastic-targeting signal peptide, I- intron, AttP and AttB - 
PhiC31 integrase recombination sites, nos - nopaline synthase terminator, 3’ NTR - non-
translated region, Integrase - Streptomyces phage PhiC31 integrase. Example of 3’ 
module with gene of interest being pCocSH is shown. The scale bar is located at the 
bottom of the figure. 
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Figure 6. Flowchart of transient expression of cocaine hydrolase variants of pBChE. 
Agrobacterium tumefaciens cells harboring the deconstructed TMV-vectors containing 
the pBChE variant genes (A) were infiltrated into leaves by applying vacuum to whole-
submerged N. benthamiana plants (B1) or by leaf injection with needle-less syringe into 
leaves (B2). Plants were then grown post inoculation for up to 12-16 days (C) during 
which time the vectors of the ICON system work together to recombine in the nucleus. 
The recombined modules are spliced and exported to the cytoplasm where the assembled 
vector can replicate and be translated into the pCocSH protein which is targeted to the 
secretory pathways, as well as other proteins used for RNA replication and cell-to-cell 
movement (D).  
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Agrobacteria Infiltration for Transient Recombinant Protein Production in Plants  
 TMV-based vectors were electroporated into A. tumefaciens strain GV3101 
electro-competent cells. Transformed cells were screened via antibiotic selection as well 
as colony screen PCR and only positive colonies were used for downstream studies. 
Bacteria cultures were grown at 30ºC until mid-logarithmic phase, pelleted by 
centrifugation at 4,500× g for 20 minutes at room temperature then resuspended in 10 
mM 2-(N-morpholino)ethanesulfonic acid (MES), 10 mM magnesium sulfate 
heptahydrate, pH 5.5 buffer. Wildtype (WT) N. benthamiana plants were infiltrated either 
by needle-less syringe injection or by whole-plant vacuum infiltration. Leaves infiltrated 
with each variant were harvested at indicated time points and analyzed by the Ellman-
assay (discussed in more detail under subheading Enzymatic Assay and TSP 
Concentration Determination) and an immunoassay to determine the expression level of 
the BChE enzyme variants (Figure 6).  
Agrobacteria-Mediated Transformation for Stable Recombinant Protein Production in 
Plants 
 Stable transgenic N. benthamiana plants expressing pCocSH were established by 
transforming A. tumefaciens strain LBA4404 with pTM 835 (pCocSH + SEKDEL which 
will henceforth be designated as pCocSHER) or pTM 904 (pCocSH) (Figure 7). Sterile 
WT leaf explants from WT plants grown in sterile conditions were transformed with 
these cultures using the Agrobacterium-mediated method, as previously described (Figure 
7) (Geyer et al., 2007). Briefly, Agrobacteria cultures were grown to mid-logarithmic 
phase, centrifuged for 10 minutes at 2000 ×g at 4ºC and resuspended in Agrobacterium-
induction media (AIM, 2.15 g/L Murashige and Skoog (MS) salts, 0.5 mg/L pyridozine, 
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0.5 mg/L nicotinic acid, 2 mg/L thiamine HCl, 100 mg/L myoinositol, 0.9 g/L glucose, 
1.95 g/L N-morpholino ethanesulfonic acid (MES), pH 5.2) to an optical density 
(O.D.)600 of approximately 0.4. Sterile leaf explants were cut into squares and co-
cultivated with these cultures using the well-established Agrobacterium-mediated 
method. Briefly, sterile leaf discs were transferred to non-selective co-cultivation plates 
(4.3 g/L MS salts, 30 g/L sucrose, 1 mL/L 1000x Gamborg’s B5 Vitamin solution, 6 g/L 
agar, pH 5.6). After 2 days of incubating in a temperature-controlled growth room, leaf 
discs were transferred using sterile technique to shoot selection media (4.3 g/L MS salts, 
25 g/L sucrose, 0.1 mg/L 1-naphthalene acetic acid (NAA), 1 mg/L 6- 
benzylaminopurine (BA), 8 g/L agar, 200 mg/L kanamycin and 300 mg/L 
Ticarcillin/Timentin). Transformed discs were incubated on shoot selection media in a 
growth room until undifferentiated cell masses called calli formed. The calli remained on 
plates until shoots formed and once the shoots grew to approximately 1cm in height they 
were then excised and transferred to selective rooting and shooting media now in tubs, 
containing 2.15 g/L MS salts, 30 g/L sucrose, 1 mL/L 1000x Gamborg’s B5 Vitamin 
solution, 8 g/L agar, 200 mg/L kanamycin and 300 mg/L Ticarcillin/Timentin. 
Regenerated plants were screened for BChE activity by Ellman assay and the highest 
expressing plants were transferred to soil and seeds were collected. Subsequent 
generations (T1 and later) grown on soil were screened by kanamycin spray selection. For 
antibiotic spray of the seedlings, kanamycin was prepared in water for a final 
concentration of 500 mg /L and leaves were sprayed daily in sufficient quantity to wet the 
surface of the leaves as soon as the first true leaves appeared (Weide et al., 1989; Xiang 
  
40 
et al., 1999). Those plants developing chlorosis in response to the antibiotic selection 
were disposed of.  
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Figure 7. Development of stable transgenic pCocSH-expressing plants.  
Binary vectors (pGPTV-Kan) containing the pCocSH gene with or without C-terminal 
SEKDEL were transformed into A. tumefaciens strain LBA4404 (bottom left), that was 
then incubated with sterile leaf explants (top left). Transformed cells from the explants 
were allowed to develop into an undifferentiated cell mass (callus) on selective media 
containing kanamycin. Calli were transferred to selective media containing hormones 
specific for shoot formation followed by transferring newly formed shoots to rooting 
media to allow root formation (top right). Regenerated whole plants were tested for 
BChE activity and high expressers were transferred to soil (bottom right). 
 
  
42 
Protein Extraction and Initial Clarification 
 For small scale protein extraction (less than 0.5 g fresh weight leaf material), N. 
benthamiana leaf material was weighed and either flash frozen in liquid nitrogen and 
stored at -80ºC or immediately submerged in cold 50 mM sodium phosphate buffer, pH 
8.0 (1 mL buffer/ 0.2 g leaf). Leaf material was mechanically broken in the presence of a 
ceramic bead by FastPrep (MP Biomedicals) 2 × 30 seconds and subsequently 
centrifuged at 4ºC for 20 minutes at 13,000 ×g to separate the total soluble proteins 
(TSP) in the supernatant from the insoluble pellet. Half of the supernatant was stored at 
4ºC for immediate analysis while the other half was kept at -80ºC for long term storage. 
Large-scale preparations were extracted by blending in the presence of cold extraction 
buffer (50 mM sodium phosphate, 150 mM sodium metabisulfite, 1 mM EDTA, pH 8.0) 
at a ratio of 1 g leaf: 2 mL buffer, although if necessary more buffer was added to 
facilitate homogenization. Extract was filtered through double-layer miracloth and 
centrifuged at 22,000 ×g for 30 minutes followed by pH adjustment to pH 5.0 and further 
clarification by ammonium sulfate ((NH4)2SO4) precipitation with a 40% initial cutoff 
followed by stirring at 4ºC for 1 hour then centrifugation at 22,000 ×g to pellet 
undesirable protein contaminants. The supernatant was then brought up to 70% 
ammonium sulfate and stirred at 4ºC for 1 hour followed by pelleting at 27,500 ×g for 30 
minutes. The pellet containing pBChE was resuspended in cold 1x phosphate buffered 
saline (PBS) pH 7.4 (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 
pH 7.4) and dialyzed overnight against 1× PBS pH 7.4 to remove salts and sodium 
metabisulfite. The clarified protein preparation was then subject to sequential affinity 
chromatography steps with Concanavalin-A (ConA)-sepharose followed by procainamide 
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affinity chromatography as previously described (Geyer et al., 2010b). ConA sepharose 
affinity chromatography utilizes a lectin-bound sepharose resin to bind glycans such as 
those found on glycoproteins. Briefly, the sample and resin were equilibrated in 20 mM 
NaPi, 500 mM NaCl pH 8.0. Bound protein was eluted with a stepwise (0.05-1 M) 
increasing concentration of methyl-α-D-mannopyranoside solubilized in 20 mM NaPi, 
500 mM NaCl pH 8.0. For concentrating pCocSH, a 30 kDa cutoff centrifugal filter 
(Merck Millipore) was used at 3,500 ×g until desired concentration was reached. 
Enzymatic Assay and TSP Concentration Determination 
 The spectrophotometric Ellman assay was used to assess basic BChE activity with 
butyrylthiocholine iodide (BTC) (Sigma) as the substrate (1 mM). Assays were run at 
30°C in a Spectramax 190 spectrophotometer (Molecular Devices) as previously 
described (Geyer et al., 2005). Briefly, the Ellman assay works by incubating the enzyme 
in the presence of its preferred substrate, BTC. In order to measure enzymatic activity 
against this substrate, activity is measured by increase in yellow color (absorbance is 
measured at 412nm over 30 minutes) that is produced from thiocholine when it reacts 
with a supplied dithiobisnitrobenzoate ion. Therefore, when BChE breaks down BTC into 
thiocholine, that thiocholine molecule will react with the dithiobisnitrobenzoate to 
produce the yellow anion of 5-thio-2-nitro-benzoic acid (NTB) which the absorbance of 
the solution can be measured by the spectrophotometer as O.D. (absorbance units)/min 
which a no-enzyme blank is then subtracted from. Using the Beer-Lambert law and 
extinction coefficient of NTB (ε = 13,600 M−1 cm−1), the concentration of product being 
produced per minute in nmol/min can be calculated and this is defined as one milliunit 
(mU). Reports have claimed that an ε = 14,150 M−1 cm−1 is also appropriate (Collier, 
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1973; Riddles et al., 1983) however for these experiment 13,600 M−1 cm−1 was used. TSP 
levels were determined by the Bradford protein assay using Bio-Rad Protein Assay 
Reagent (Bio-Rad) and comparing to bovine serum albumin (BSA) standard as described 
(Mor et al., 2001). 
SDS-PAGE and Western Blot 
 Soluble protein samples were prepared by addition of 6x sodium dodecyl sulfate 
(SDS) sample buffer for a final concentration of 1× SDS sample buffer (0.0625 M Tris 
pH 6.8, 2% SDS, 10% glycerol, 0.1 M dithiothreital (DTT), 0.01% bromophenol blue), 
heated at 100ºC for 2-5 minutes to denature proteins, and resolved by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 8% polyacrylamide gels 
which were run at 100 V until proteins were well separated. Gels were then stained with 
silver stain (Thermoscientific) or transferred to nitrocellulose membranes at 20 V for 25 
minutes. Membranes were blocked with phosphate buffered saline with tween-20 (0.1%) 
(PBST) containing 5% dry milk for at least 1 hour at room temperature while shaking. 
Membranes were then immunodecorated with rabbit polyclonal anti-BChE antibodies in 
blocking buffer (1: 5,000) (kind gift of Dr.Oksana Lockridge) for at least 1 hour at room 
temperature followed by a 3× rinse in PBST then subsequent 10 minute wash in PBST. 
They were then incubated with anti-rabbit IgG-Horse Radish Peroxidase (HRP) 
antibodies (1: 10,000) in blocking buffer for at least 1 hour at room temperature followed 
by 3×10 minutes washes in PBST (for a total of 30 minutes) and then developed with 
enhanced chemiluminescence luminol reagent (Santa Cruz), and exposed to film. 
 Estimation of the concentration of pBChE variants was conducted using a 
quantitative immunoblot assay with crude and highly purified samples of plant-derived 
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BChE and using highly purified WT plasma-derived hBChE whose molar concentrations 
were previously determined to generate a standard curve (Geyer et al., 2009; Geyer et al., 
2010a). In order to estimate the unknown protein concentration correlating to known 
enzymatic activity levels, films were scanned using an HP4050 (Helwett-Packard) 
scanner and high resolution (at least 600 dpi). Greyscale images were used for 
densitometry analysis with Image J Software and data was used to plot standard curve 
fitted by linear-regression (GraphPad Prism). Samples of variants with unknown 
concentrations were resolved alongside the standards and densitometry results together 
with the regression equations were used to obtain concentration of the BChE variants. 
Several dilutions of samples were applied to make sure samples were well within the 
linear range of the standard curve (Figure 8). 
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Figure 8. Quantitative western blot of pCocSH. 
Quantification of pCocSH with C-terminal 6xHis tag (pTM 783- right panels) and 
without C-terminal modifications (pTM949- left panels). A. Raw image of immunoblot 
showing lanes corresponding to known WT hBChE (100-12.5 ng/well) and a range of 
unknown quantities of pCocSH loaded based on enzymatic activity (mU). A major BChE 
band is typically seen between 72-95 kDa. Two distinct bands within this range at this 
position are also sometimes detectable resulting from hybrid glycan structures (Geyer et 
al., 2010b). Additionally a degradation product of approximately 55 kDa is also 
sometimes observed which previous reports indicating is likely a result of N-terminal 
truncation (Schneider et al., 2014b). Films were scanned, images were cropped and 
converted to grey scale then densitometry analysis was performed using Image J 
software. B. Standard curve generated from the pixel area Image J results. C. Table of 
specific activity determined from quantitative western blot for pBChE variant 
(A199S/F227A/S287G/A328W/Y332G) with and without SEKDEL. Similar methods 
were used to determine the specific activity for Variants 2, 3 and 5 as well. 
 
  
47 
Results 
 The Mor lab has previously described the production of a double mutant of BChE 
A328W/Y332A (Variant 1) in stably transgenic plants (Geyer et al., 2008). This mutant 
has enhanced hydrolytic activity toward (-)-cocaine (Sun et al., 2001; Sun et al., 2002a; 
Masson et al., 2003). The catalytic prowess of Variant 1 was sequentially improved by 
introducing additional or different site-directed changes to create Variants 2, 3, 4 and 5. 
High-Level Recombinant Protein Production  
 Using the magnICON expression system (Santi et al., 2006), deconstructed-TMV-
based vectors were introduced into WT tobacco plants by infiltration either by using 
needle-less syringe injection or by application of vacuum on whole plants (leaves and 
stems) submerged in Agrobacteria suspensions. Expression of all four of the pBChE 
variants using this system was confirmed by enzymatic activity (Figure 9). In order to 
determine how many mg BChE per kg leaf, the enzymatic activity had to be converted 
from the output of the Ellman assay to mg BChE The specific activity of WT hBChE, or 
the number of Units corresponding to mg amount of protein, is established at 
approximately 700-750 U/mg BChE (Nachon et al., 2002; Saxena et al., 2005). We did 
not expect this to be the same specific activity for these mutants as amino acid mutations 
can change the enzyme’s affinity for and efficiency against its preferred substrate, in this 
case the BTC. Therefore slower hydrolysis of the substrate could be the same amount of 
protein, it simply does not hydrolyze as efficiency due to the effects of the mutations. To 
test for this, quantitative western blots were performed for all variants by loading based 
on known activity. The protein content loaded was then determined by comparison to a 
standard curve of WT hBChE and the U/mg specific activity for each mutant was 
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established similar to the results shown in Figure 5. Once the respective specific activities 
were determined, we were then able to convert the enzymatic activity measurements into 
mass units (e.g. mg BChE). In turn, these can be expressed in terms of the plant fresh 
weight, or concentration as shown in Figure 6. The specific activity of the most relevant 
variant, pCocSH was found to be around 36 U/ mg pCocSH and this was used for all 
subsequent analyses for this mutant.  
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Figure 9. Transient plant expression of pBChE variants over time. 
Variants of BChE designed for cocaine hydrolysis accumulate over time in plants 
infiltrated with TMV-vectors. Multiple (2 or 3) different leaf samples (0.2 g fresh weight) 
from different plants were harvested at the given time points. Protein levels determined 
from the 0.2 g-leaf sample were then extrapolated to determine estimated protein 
accumulation in 1 kg of fresh leaf material. Mean protein level values ± SEM were 
determined based on activity assays in conjunction with immunoassays from plants 
infiltrated with magnICON vectors expressing Variant 2, Variant 3, Variant 4, and 
Variant 5.  
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` Multiple 0.2 g leaf samples from different plants were assayed per time point for 
BChE activity. Peak expression time was around 14 days but with some variation among 
the variant forms (14-17 days). Accumulation levels varied considerably between the 
various mutants and ranged from 16 to 100 mg per kg fresh weight leaf material. At this 
time the laboratory received new integrase and 5’ ICON modules and these were 
transformed into new stocks of A. tumefaciens. Furthermore, the growth conditions of the 
plants were optimized and changed from greenhouse to growth chamber conditions. 
These changes in combination likely led to the slight shift in peak expression and slightly 
higher accumulation of pCocSH6xHis when comparing the early time courses (Figure 9) to 
later ones (Figure 10). Transient expression levels were compared between varying C-
terminal constructs of pCocSH and pTM949 (pCocSH with no C-terminal modification) 
had surprisingly high accumulation levels (Figure 10). Protein expression of variants 
2,3,4, and 5 was also confirmed by immunoblot with BChE-specific antibodies (Figure 
11). A major BChE band is typically seen between 72-95 kDa which is larger than the 
theoretical non-glycosylated mass of the enzyme (with no c-terminal modification) which 
is approximately 65 kDa. Two distinct bands within this range at this position are also 
sometimes detectable resulting from hybrid glycan structures (Geyer et al., 2010b). 
Additionally a degradation product of approximately 55 kDa is sometimes observed 
which previous reports indicating is likely a result of N-terminal truncation (Schneider et 
al., 2014b). 
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Figure 10. Transient plant expression of C-terminal variants of 
pCocSH over time.  
Mean % TSP is shown ± SEM. After the time course in Figure 
6, freshly transformed ICON Integrase and 5’ modules were 
used and plant growth conditions were changed. Under these 
optimized conditions, time courses were conducted for C-
terminal variants of pCocSH. Time courses were conducted 
separately at different times using an O.D.600 of either 0.1 or 0.4 
for infiltration using either the Needleless (N) or Vacuum (V) 
infiltration methods. Multiple (2 or 3) different leaf samples (0.2 
g fresh weight) from different plants were harvested at the given 
time points and assayed by the Ellman-assay and converted to 
mg BChE based in the determined specific activity for pCocSH 
to determine mg BChE per kg leaf fresh weight (top). Total 
Soluble Protein (TSP) content in these samples was determined 
by the Bradford assay to establish mg BChE per mg TSP 
(bottom). 
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Figure 11. Immunoblot detection of all cocaine hydrolase variants of pBChE. 
A, B, C and D verify the presence of BChE protein during timecourses for Variants 2, 3, 
4 and 5 respectively. 20 ng of plant-derived WT BChE was included as a positive control 
for each western. The 72 kDa band of the protein marker is indicated with a red arrow for 
size reference.  
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 The pCocSH6xHis and pCocSHER ranged between 100 and 350 mg/kg respectively. 
Levels reached upwards of 700 mg BChE/ kg leaf material in pCocSH derived from 
pTM949 and this has been observed to reach even higher levels >1 g/kg (data not shown) 
however there is typically increased variability between plants at these stages. The % 
TSP, or mg BChE per mg TSP, also reached high levels. Using the vacuum infiltration 
method with a bacterial density of O.D.600 0.1, the pTM949 pCocSH variant reached 
approximately 18% TSP using the needleless infiltration method. The pCocSH, 
pCocSHER and pCocSH6xHis variants also reached high levels of approximately 8%, 7% 
and 4% TSP respectively. The variation in accumulation of pCocSH using vacuum 
(~18% TSP) and needleless (~8% TSP) could be a result of excess damage to the leaves 
that underwent the needleless infiltration if excess pressure was used during the 
infiltration. It should be noted that although comparable procedures were followed 
between the three infiltrations, the pTM949 time course was done at a later time than 
pTM833 and pTM783 and the growth chamber temperature had been lowered to 23-25ºC 
compared to 26-28ºC which the pTM833 and pTM783 post-infiltrated plants were housed 
in. It will be interesting to investigate if the decrease in temperature had an effect on 
expression levels of pCocSH.  
 Transient expression has been shown to reach much higher accumulation than 
standard transgenic stable expression for secretory proteins (Komarova et al., 2010). 
However, it is advantageous to have long-term storage and no need for recurrent 
infiltration. Stable lines were created for pCocSH with (pTM835) and without SEKDEL 
(pTM904) and screened based on BChE activity (Figure 12).  
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Figure 12. Screening of BChE activity in stable T0 transgenic plant lines.  
The highest expressers for each line were (plant #39 for pTM 904 and plant #83 for pTM 
835). 
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 The highest expressing line of pTM835 was #83, however the second highest 
expressing plant, #23, was harvested for seed because it produced seed far sooner than 
#83 and had a healthier phenotype. The pTM904 line (#39) as well as several other high 
expressing lines were harvested for seed and subsequent generations were grown. After 
kanamycin selection, the second generation of the noted lines were grown in a large batch 
and harvested. Prior to extraction 3-4 plants were tested for BChE content and yielded 
approximately 3% TSP and 2% TSP for pTM835 and pTM904 respectively (Figure 13). 
This indicates that in stable transgenic plants, the pCocSH variant with ER-retention 
signal (pTM 835) accumulated to higher levels than the construct without this KDEL 
signal (pTM904). Conversely, the plants expressing the protein transiently, the pCocSH 
variant without ER-retention signal (pTM 949) accumulated to higher levels than the 
construct with the KDEL signal (pTM 833). It is possible that the different mechanism 
and speed at which protein is produced using the two different systems could account for 
this apparent opposite performance. In stable transgenic plants, the presence of a C-
terminal ER-retention signal is well known to often lead to increased protein 
accumulation which coincides with what we observed in our transgenic lines (Wandelt et 
al., 1992; Fiedler et al., 1997; Conrad and Fiedler, 1998; Geyer et al., 2007). The better 
performance of the transient expression variant without KDEL may be a result of the 
much higher expression achieved with this system. The high level of protein 
accumulation in a short period of time may put pressure on the folding machinery of the 
ER. When an ER-retention signal is incorporated that would lead to even higher amounts 
of protein being accumulated in the ER that may lead to increased ER stress and a 
subsequent decreased protein accumulation compared to the transient variant without 
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KDEL. This will be discussed further in the discussion section of Chapter 3. Presence of 
BChE in material purified from the stable transgenic lines was also confirmed by 
immunoblot using BChE-specific antibodies (data shown for pTM835) (Figure 14). 
Stably produced protein was subsequently purified similarly to transiently expressed 
pCocSH6xHis that was highly purified for downstream animal studies (Figure 15). 
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Figure 13. pCocSH yield in high expressing stable transgenic lines. 
Mean ± SEM of BChE yield of high expressing stable transgenic lines. pCocSH 
(blue) are progeny of line # 39, the highest expressing line from the screen shown in 
Figure 8, and pCocSHER (maroon) are progeny of line # 23, the 2nd highest 
expressing line from the screen. Multiple (3 or 4) different leaf samples from 
different transgenic plants were harvested once fully grown and % TSP was 
determined by enzymatic activity and Bradford analysis.  
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Figure 14. Immunoblot detection of pCocSHER in stable transgenic plants.  
Lanes represent Elutions 2-5 from procainamide purification eluting with increasing 
concentrations of NaCl. WT N.b is WT N. benthamiana crude TSP extract. Varying 
amount of BChE were loaded based on activity (either 1.5 or 0.8 mU per well). 
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Figure 15. Highly purified pCocSH.  
pCocSH was loaded based on activity and subject to SDS-PAGE. 50 mU, 1.5 mU and 0.8 
mU pCocSH were loaded for Coomassie (left), silverstain (middle), and immunoblot 
(right) detection respectively. WT N. benthamiana crude plant extract control (C) was 
loaded for comparison. 
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Discussion 
 N. benthamiana was successfully used to express different cocaine hydrolase 
variants of pBChE, including the most efficient cocaine hydrolyzing variant of BChE 
designed to date, pCocSH (A199S/F227A/S287G/A328W/Y332G) (Larrimore et al., 
2013; Xue et al., 2013a; Zhan et al., 2014). The pCocSH variant of BChE designed for 
enhanced cocaine hydrolysis has only been expressed thus far in CHO cells and HEK 
cells with expression levels only having been reported from the stable CHO lines 
reaching approximately 10 mg/L (Xue et al., 2013a). We have shown that using the 
magnICON transient expression system, pCocSH levels reaching upwards of 700 mg 
recombinant pBChE per kg leaf material can be reached. Additional C-terminal forms of 
this cocaine hydrolase also reach high levels ranging from approximately 170 mg/kg 
(pCocSH6xHis) to approximately 400 mg/kg (pCocSHER). Although the pCocSH variant 
with no C-terminal modification had very high accumulation levels compared to the other 
pCocSH variants, these time course studies were not completed in tandem nor were the 
same infiltration conditions used. The high expressing pCocSH pTM949 produced the 
highest yield using the vacuum infiltration method with an inoculation solution having an 
O.D.600 of 0.1. The constructs of pCocSH6xHis (pTM783) and pCocSHER (pTM833) were 
infiltrated using the needleless infiltration method with an O.D.600 of 0.4 in these 
experiments. Furthermore, the temperature of the growth chamber in which the plants 
were grown was 26-28°C at the time of the pTM833 and pTM783 infiltrations and was 
lowered to 23-25°C during the time of the pTM949 time course. Unpublished 
observations by a close collaborator have shown this slight temperature shift can alter 
expression levels depending on the expression vector. It will be interesting to directly 
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compare production under different temperatures for future studies. The purpose of the 
studies shown here was to confirm the expression of cocaine hydrolyzing variants in 
plants and to estimate recombinant protein yields. It will be interesting to conduct a side-
by-side comparison of all of the constructs using the same infiltration conditions, with 
plants grown under the same conditions, and this is currently under investigation by the 
Mor lab. 
 Stable transgenic lines are another advantageous plant-based production method 
for cocaine hydrolase variants of pBChE due to ease of scalability. Furthermore 
Agrobacterium-mediated transformation only has to be done one time and once stable 
lines are generated seeds can be stored long-term then brought out and regrown 
immediately when protein is needed. Additionally, stable transgenic plants expressing 
pBChE are capable of producing a tetrameric form of BChE that has desirable 
pharmacokinetic qualities, which will be discussed in Chapter 4. Yield of pCocSH in 
stable plants was lower than the rapid transient expression based on the MagnICON 
system, however efficient expression levels (as high as 3% TSP) were achieved 
nonetheless. Incorporation of a C-terminal SEKDEL ER retention signal can lead to 
increased accumulation of ER-targeted recombinant proteins presumably because the ER 
is a favorable organelle for protein folding and storage (De Meyer and Depicker, 2014) 
and indeed this was observed in the stable lines created in this study (Figure 13). 
 This approach led to successful accumulation of the most efficient BChE-based 
cocaine-hydrolase when the gene was either transiently expressed using a deconstructed 
TMV-based system (magnICON) or integrated stably in the plant genome. In order to 
utilize these enzymes as a possible anti-cocaine treatment, a sustainable, cost-effective 
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supply of the protein must be established. Here we demonstrated the proof-of-principle 
that plants are an attractive means of rapidly producing cocaine-hydrolyzing variants of 
BChE in quantities relevant for clinical use. 
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3 BIOCHEMICAL CHARACTERIZATION OF  
PLANT-DERIVED COCAINE HYDROLASE VARIANTS OF BCHE  
 
Abstract 
. Butyrylcholinesterase (BChE) is an enzyme with broad substrate and ligand 
specificities and may function as a generalized bioscavenger by binding and/or 
hydrolyzing various xenobiotic agents and toxicants, many of which target the central 
and peripheral nervous systems. Variants of BChE were rationally designed to increase 
the enzyme’s ability to hydrolyze the psychoactive enantiomer of cocaine. These variants 
were cloned, and expressed using the magnICON transient expression system in plants 
and their enzymatic properties were investigated. In particular, we explored the effects 
that these site-directed mutations over the enzyme kinetics with various substrates of 
BChE. We further compared the affinity toward various anticholinesterases including 
organophosphorous (OP) nerve agents and pesticides of these BChE variants relative to 
the wild-type enzyme. In addition to serving as a therapy for cocaine addiction-related 
diseases, enhanced bioscavenging against other harmful agents could add to the 
practicality and versatility of the plant-derived recombinant enzyme as a multivalent 
therapeutic. 
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Introduction 
 BChE is a promiscuous enzyme capable of binding and/or hydrolyzing a variety 
of compounds including many natural and man-made toxicants of the central and 
peripheral nervous system such as organophosphorous anticholinesterases, acetylcholine-
receptor antagonists, and psychoactive plant alkaloids (McGehee et al., 2000; Taylor, 
2001; Decker, 2005; Khan et al., 2005; Loizzo et al., 2008). Unlike the highly selective 
homologous enzyme acetylcholinesterase (AChE), BChE is capable of hydrolyzing long-
chain choline esters, ghrelin (a hormone peptide) and cocaine (Masson et al., 1998; 
Ashani, 2000; Koetzner and Woods, 2002; Mesulam et al., 2002; Chen et al., 2015). 
Exogenously supplied BChE can augment the bioscavenging capacity of the endogenous 
enzyme and provide broad protection by sequestering anticholinesterase agents and other 
toxicants before they are able to inhibit the physiologically important AChE or other 
targets. Moreover, recombinantly produced BChE variants with improved binding 
affinities and catalytic prowess, can created to improve on the parameters of the native 
wild-type enzyme. 
 The hydrolytic activity of human BChE (hBChE) against cocaine is measurable 
and provides one of the major detoxification pathways for the drug, generating the non-
psychoactive products ecgonine methyl ester and benzoic acid. Mutants of BChE have 
been rationally-designed with the goal of creating a highly efficient cocaine hydrolase in 
order to provide an enzyme-based therapy to treat drug overdose and addiction (Zheng 
and Zhan, 2011). It is not easily predictable how mutations of the enzyme will alter the 
enzyme’s affinity and interaction with substrates other than (-)-cocaine. When designing 
cocaine-hydrolyzing variants, the enzymes’ kinetics with the physiologically important 
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neurotransmitter, acetylcholine (ACh), was closely investigated in situ, in vitro, and in 
some cases in vivo to ensure selectivity for cocaine over ACh as any significant increase 
in ACh hydrolysis could have negative impacts on cholinergic transmission (Xue et al., 
2011). Investigating the kinetic parameters of additional substrates such as the synthetic 
ACh-like molecule called butyrylcholine (BCh), however, can also offer insight into the 
effects mutations can have on the enzyme. Unlike ACh, BCh does not naturally exist in 
the human body, yet it is the preferential substrate of BChE and is commonly used as a 
tool to help distinguish between BChE and AChE. The preferential substrate of WT 
AChE is ACh and the preferential substrate of WT BChE is BCh. Butyrylthiocholine 
(BTC) and acetylthiocholine (ATC) are respective analogs of BCh and ACh and are 
commonly used substitutes for the latter substrates in the laboratory as they are similar 
substrates yet allow for easy detection of enzymatic activity. Interestingly, the preferred 
substrates of either enzyme, when present at high concentration, have strong and opposite 
allosteric effects on their respective enzymes. In the presence of high concentrations of 
ACh (i.e. > 5 mM), AChE exhibits substrate inhibition (Shafferman et al., 1992) while 
BChE exhibits substrate activation in the presence of high concentrations of BCh 
(Masson et al., 2001). Mutants of BChE, especially those designed for efficient cocaine 
hydrolysis, have not been studied to observe how these mutations might affect these 
kinetic traits at high substrate concentrations.  
 Mutations to BChE, although designed with the goal of improved (-)-cocaine 
hydrolysis, could also have an effect on the binding affinity of BChE with various 
inhibitors. WT BChE stoichiometrically binds OP agents and some carbamate nerve 
agents, that in effect protects the physiologically important sister enzyme, AChE. BChE 
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has since been widely investigated as a nerve-agent bioscavenger to be used as a 
prophylactic treatment to prevent nerve-agent intoxication. A current goal in the field is 
to make an improved bioscavenger and in 2013 Nachon, et al. discussed the progress 
made to this end (Nachon et al., 2013). Because WT BChE cannot breakdown these 
agents and bind stoichiometrically, efforts have been made toward developing a catalytic 
(and thus ‘reusable’) bioscavenger as well as pseudocatalytic scavengers (ones that can 
be regenerated with co-administration of reactivators) (Nachon et al., 2013). 
 Another approach is to improve the stoichiometric scavenging of BChE by 
increasing the protein’s affinity for neurotoxins and then produce large amounts of these 
high-affinity BChE-based proteins using recombinant expression platforms. In 2008, 
Geyer et al. found that A328W/Y332A mutations which were designed to increase 
cocaine hydrolysis, also resulted in enhanced ability to bind various inhibitors (Geyer et 
al., 2008). We hypothesized that other cocaine hydrolase variants of BChE would have 
either a similar, or perhaps further improved, affinity for various nerve agents. 
 We hypothesized that by mutating the enzyme for these purposes, the enzyme’s 
activity toward its other substrates and binding partners will also be affected. We 
subsequently tested their potential to bioscavenge OP compounds and hydrolyze various 
cholinesterase substrates. Here, we report the complex kinetic behavior of the plant-
derived cocaine hydrolase mutants of BChE and enhanced OP scavenging ability, with 
potential for multivalent uses for this anti-cocaine treatment.  
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Materials and Methods  
Transient Recombinant Protein Production in Plants  
 All expression vectors (see Materials and Methods of Chapter 2) were 
electroporated into Agrobacterium tumefaciens strain GV3101 electro-competent cells. 
Transformed strains were screened via antibiotic selection as well as colony screen PCR 
and only positive colonies were used for downstream studies. Bacteria cultures were 
grown at 30ºC until mid-logarithmic phase, pelleted by centrifugation at 4,500 ×g for 20 
minutes at room temperature then resuspended in 10 mM 2-(N-morpholino) 
ethanesulfonic acid (MES), 10 mM magnesium sulfate heptahydrate, pH 5.5 buffer. 
Plants were infected either by needle-less syringe injection or by whole-plant vacuum 
infiltration. Leaves infiltrated with each variant were harvested at the respective day of 
peak expression as determined in previous reports (Larrimore et al., 2013). 
Kinetic Assays 
 BChE activity was assayed by a modified Ellman assay as described in Chapter 2 
with the following changes. Activity was measured using either BTC (Sigma) or ATC 
(Sigma) at 30°C in a Spectramax 190 spectrophotometer (Molecular Devices). Total 
soluble protein (TSP) levels were determined by the Bradford protein assay (Bradford, 
1976) using Bio-Rad Protein Assay Reagent (Bio-Rad) and comparing to bovine serum 
albumin (BSA) standard as described (Mor et al., 2001). Enzymatic hydrolysis by 
purified WT plasma-derived human (h) BChE, WT plant-optimized (p) BChE or crude 
plant extract of cocaine hydrolase variants was measured in 96-well plate format over 
varying concentrations of BTC or ATC in final well volume of 200 µL. To account for 
product formed by self-hydrolysis, initial velocity of non-enzymatic hydrolysis was 
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subtracted from initial velocity of the enzyme-catalyzed reactions and reaction rates were 
then plotted as a function of substrate concentration. 
 To measure cocaine hydrolysis, a sensitive radiometric assay was used as 
previously described (Brimijoin et al., 2002). Briefly, [3H] (-)-cocaine labeled on the 
benzene ring (50 Ci/mmol), purchased from PerkinElmer Life Sciences (Boston, MA), 
was used as a substrate with varying concentrations of (-)-cocaine. In the presence of a 
fixed quantity of enzyme this reaction proceeded at room temperature (25°C) until 
stopped by the addition of 20 mM HCl. Any neutralized, liberated, labeled benzoic acid 
was then extracted with a toluene-based fluor and measured by scintillation counting. 
Inhibition  
 Purified WT hBChE, WT pBChE, or crude plant extract of cocaine hydrolase 
variants was incubated in 96-well plate format with indicated concentrations of paraoxon 
(O,O-Diethyl-p-nitrophenyl phosphate), neostigmine bromide (Benzenaminium,3-
[[(dimethylamino)carbonyl]oxy]-N,N,N-trimethyl-,bromide), iso-OMPA 
(Tetra(monoisopropyl)pyrophosphortetramide), DFP (diisopropyl fluorophosphate), 
procainamide (4-amino-N-(2-diethylaminoethyl) benzamide) or BW284c51 (1,5-bis(4-
allyldimethylammoniumphenyl)pentan-3-one dibromide) (all purchased from Sigma) for 
30 minutes at room temperature followed by activity measurements based on modified 
Ellman assay using 1 mM BTC as the substrate. IC50 values were determined by non-
linear regression (GraphPad Prism) fit according to equation (1). 
              (1) 
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The inhibition rate constant (ki) of one variant, Variant 4, treated with paraoxon was 
determined as previously described (Mionetto et al., 1997). 
Purification  
 All extraction and purification procedures were carried out at 4ºC. Large-scale 
preparations were made as described in Chapter 2. Briefly, leaf tissue was homogenized 
by blending in the presence of 50 mM sodium phosphate, 150 mM sodium metabisulfite, 
1 mM EDTA, pH 8.0. Extract was filtered through double-layer miracloth and 
centrifuged at 22,000 ×g for 30 minutes followed by pH adjustment to pH 5.0 and further 
clarification by ammonium sulfate precipitation. The pellet was resuspended in cold 1× 
PBS and dialyzed overnight against 1× PBS, pH 7.4 to remove salts and sodium 
metabisulfite. The clarified protein preparation was then subject to sequential affinity 
chromatography steps with Concanavalin (Con-A) sepharose which was then in some 
instances followed by procainamide affinity chromatography as previously described 
(Geyer et al., 2010b). 
SDS-PAGE and Western Blot  
 Plant-derived protein preparations were resolved by SDS-PAGE on 8% 
polyacrylamide gels followed by silver staining using Pierce Silver Stain Kit 
(Thermoscientific), or protein was transferred to nitrocellulose membrane and 
immunodecorated with rabbit polyclonal anti-hBChE antibodies (1:10,000) (kindly 
provided by Dr. Oksana Lockridge) and anti-rabbit IgG-Horse Radish Peroxidase 
secondary antibodies (1:5000) (Santa Cruz Biotechnology) followed by 
chemiluminescence analysis using western blotting luminol reagent (Santa Cruz 
Biotechnology).  
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Size Exclusion HPLC 
 Size exclusion high pressure liquid chromatography (SEC-HPLC)-based 
fractionation of purified preparations of Variant 4 (pCocSH) either with C-terminal 
SEKDEL endoplasmic reticulum (ER) retention signal or C-terminal 6x Histidine tag was 
carried out as recently described using Alliance HPLC (Waters) with a Shodex KW-803 
column (8 x 300 mm, Kawasaki) (Geyer et al., 2010b). Mobile phase buffer used was 20 
mM Na2HPO4/NaH2PO4, pH 8.0, 200 mM NaCl, 0.04% NaN3 filtered and degassed and 
was used with a flow rate of 0.5 mL/min. Highly purified standards of known molecular 
weight were injected as internal references. Pooled fractions at indicated time points were 
collected and analyzed for cholinesterase activity via modified Ellman assay. 
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Results 
 The genes encoding WT pBChE and the cocaine hydrolase Variants 2, 3, 4 and 5 
were cloned into a deconstructed tobacco mosaic virus-based transient expression system. 
Each variant was transiently expressed in WT N. benthamiana plants as previously 
described (Larrimore et al., 2013). All kinetic analysis and inhibition studies were 
conducted using the crude clarified plant extract of the cocaine hydrolases following pH 
adjustment and ammonium sulfate clarification, except for Variant 4 (pCocSH), the most 
promising of the hydrolases, which was highly purified prior to kinetic assays where 
noted. 
Purification and Molecular Forms of Cocaine Hydrolase Variants 
 An single efficient extraction and purification strategy was developed which can 
be used for all of the plant-derived cocaine hydrolase variants described thus far (one 
example purification of pCocSH is shown in Table 3) based on initial clarification using 
ammonium sulfate and acidification of the crude plant extract followed by ConA affinity 
chromatography (Table 3). pCocSH BChE recovery between the crude ‘initial’ plant 
extract and post acidification/ 40-70% (NH4)2SO4 fractionation have been observed as 
high as > 90% recovery (data not shown), though some variation is observed between 
batches as would be expected. Yields from the ConA purification are taken relative to the 
amount of BChE that was loaded onto the column (considered as 100%). For example, all 
of the BChE in the ConA eluates constituted 40% of what was initially loaded onto the 
column (Table 3). As was previously reported, we also observed a proportion (30-50%) 
of the BChE loaded onto the ConA resin unable to be recovered. The material that is 
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recovered, however, is quite pure (Figure 16). This strategy could possibly eliminate the 
need of a secondary, in-tandem procainamide-based purification scheme. 
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Table 3. Purification of pCocSH. 
Representative example of a typical ConA purification of pCocSH from N. benthamiana  
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Figure 16. Electrophoretic identity and purity of pCocSH6xHis. 
Samples extracted from N. benthamiana were clarified and concentrated 
with ammonium sulfate (70%). Samples were then subject to ConA 
purification and eluted with stepwise increasing concentrations of methyl-
α-D-mannopyranoside then concentrated ([E1]-[E5]). Samples containing 
equal amount of BChE (based on activity), protein size marker (M) and 
uninfiltrated WT N. benthamiana control (C) were prepared and subjected 
to SDS PAGE followed by immunoblotting (top) or silverstaining 
(bottom). 
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 Molecular forms of purified preparations of pCocSH6xHis or pCocSHER were 
analyzed by size-exclusion HPLC (SEC-HPLC). It is noted that two different columns of 
the same model were used between the two pCocSH samples, resulting in slightly 
varying elution times; however, standards were included for each run with its respective 
column (Figure 17). Nearly all of the transiently expressed pCocSHER was in the 
monomeric form, identifiable by a single major protein peak eluting at the expected size 
of BChE monomers and exhibiting cholinesterase activity. A dimer peak that would 
appear near the beta amylase standard may be present but obscured within a shoulder. 
Purified pCocSH6xHis was primarily found as monomers and dimers, while tetramers were 
observed as well (Figure 17). Repeated experiments will have to be conducted to confirm 
if ER-retention plays a role in the oligomeric state of BChE. All three oligomeric forms, 
monomers, dimers and tetramers are capable of being produced using the rapid, transient 
expression platform. 
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Figure 17. Size-exclusion HPLC analysis of C-terminal variants of 
transiently expressed pCocSH. 
SEC-HPLC analysis displaying absorbance (A)280 as arbitrary units (top 
panels) and enzymatic activity of fractions collected during SEC 
analysis (bottom panels) of purified preparations of plant-derived 
cocaine hydrolase variant 4 (A199S/F227A/S287G/A328W/Y332G) 
with C-terminal SEKDEL ER retention signal (pCocSHER) (A) or C-
terminal 6x His tag (pCocSH6xHis) (B). Various highly purified 
standards of known molecular weight were also run for comparison 
(peaks of elutions are indicated with arrows). 
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In Vitro Activity of Cocaine Hydrolase BChE Variants Against Butyrylthiocholine, 
Acetylthiocholine and (-)-Cocaine 
 Substrate hydrolysis by WT hBChE, WT pBChE and cocaine hydrolase variants 
against BTC and ATC was analyzed. Both WT hBChE and pBChE exhibited typical 
substrate activation against BTC and ATC characteristic of the WT enzyme (Radic et al., 
1993; Masson et al., 2001; Boeck et al., 2002; Yang et al., 2010; Chen et al., 2012) 
(Figure 18, Figure 19). The Michaelis-Menten constant (KM ) of WT hBChE and WT 
pBChE was determined by nonlinear regression to be 16.75 ± 2.96 µM and 14.76 ± 1.26 
µM respectively, similar to previously established values (Yang et al., 2010). BChE-
catalyzed hydrolysis of BTC by Variant 3 and 4 revealed partial substrate inhibition 
reminiscent of plant-derived AChE against its preferred substrate ACh (Figure 18) 
(Evron et al., 2007; Kopecny et al., 2013). Variants 2 and 5, that differ from one another 
only by either alanine or glycine at residue 332 respectively, both exhibited apparent 
partial substrate inhibition until the substrate concentration reached approximately 2 mM 
at which point very slight substrate activation seems to appear (Figure 18). In contrast, 
Variants 2 and 5 very clearly displayed substrate activation against the smaller substrate 
ATC similar to WT pBChE and hBChE (Figure 19). Variant 3 was slightly inhibited at 
higher concentrations of ATC while Variant 4 exhibited a more classical Michaelis-
Menten kinetic profile (Figure 19).  
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Figure 18. BTC hydrolysis by cocaine hydrolase variants of pBChE. 
Enzymatic hydrolysis of BTC by WT plasma-derived hBChE, WT pBChE, and plant-
derived cocaine hydrolase variants. Plots reflect reaction rates versus substrate 
concentration for BChE-catalyzed hydrolysis of BTC. Each point represents mean 
velocity ± SEM. 
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Figure 19. ATC hydrolysis by cocaine hydrolase variants of pBChE. 
Enzymatic hydrolysis of ATC by plasma-derived hBChE, WT pBChE, and 
plant-derived cocaine hydrolase variants. Plots reflect reaction rates versus 
substrate concentration for BChE-catalyzed hydrolysis of ATC. Each point 
represents mean velocity ± SEM. 
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Table 4. Kinetic parameters of WT BChE and cocaine hydrolase variants 
against BTC and ATC substrates.  
Kinetic behavior, Michaelis Menten constant (KM), substrate inhibition 
constant (Kss) and activation factor for BChE (b) are shown. 
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 Variant 4 had considerably improved catalytic efficiency against (-)-cocaine 
(Figure 20). Catalytic activity against cocaine was tested only for this variant, that had an 
approximate 2000-fold improved catalytic efficiency against (-)-cocaine (kCAT /KM 1.1 
x109 M-1 • min-1) compared with WT pBChE (kCAT /KM 5.5 x 105 M-1 • min-1) with larger 
kCAT compared to WT pBChE (kCAT 6513 min-1 vs 7 min-1 respectively) (Figure 20).  
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Figure 20. Enzymatic hydrolysis of (-)-cocaine by WT pBChE 
and pCocSH6xHis .  
Plots reflect reaction rates versus substrate concentration for 
BChE-catalyzed hydrolysis of (-)-cocaine. Within the table are 
various kinetic parameters of both enzymes against (-)-cocaine. 
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Inhibition Analysis  
 To determine anticholinesterase scavenging ability, enzyme activity against BTC 
was analyzed following a 30-minute incubation with either reversible inhibitors 
neostigmine, irreversible inhibitors paraoxon, BChE-specific inhibitor iso-OMPA, or 
AChE-specific inhibitor BW284c51. Analysis was also conducted for the reversible 
inhibitor procainamide and irreversible inhibitor DFP (data not shown). The cocaine 
hydrolase BChE Variants 2 and 5 had dramatically increased affinity, indicated by 
decreased IC50 values, for all of the anticholinesterase agents including DFP (data not 
shown) except for the AChE-specific inhibitor iso-OMPA (Table 5). Similar to the 
A328W/Y332A variant previously described by Geyer et al., Variants 3 and 4 displayed 
enhanced affinity toward paraoxon but exhibit near WT BChE scavenging ability toward 
DFP (data not shown), neostigmine and iso-OMPA (Figure 21, Table 5) (Geyer et al., 
2008). As we would predict, all BChE variants and WT BChE enzymes were largely 
unaffected by the AChE- specific inhibitor BW284c51, however Variants 3 and 4 
appeared to be slightly more sensitive to the inhibitor at very high concentrations (Figure 
21). The BChE-specific inhibitor procainamide was of interest as it is the basis for 
procainamide-affinity chromatography used to purify BChE and it is therefore necessary 
that binding to this inhibitor not be lost if this purification strategy is to be used. 
Inhibition by procainamide was tested for the variant of most interest, Variant 4. This 
variant was found to have a slightly higher binding affinity with an IC50 of 1.8 x 10-6 M 
as compared to that of WT hBChE (5.6 x 10-5 M). The inhibition rate constants (ki) for 
inhibition by paraoxon of WT pBChE and Variant 4 BChE were determined as 
previously mentioned and were 3.14x106 and 1.7x107 M-1 min-1 respectively.  
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Figure 21. 
Inhibition profiles 
of WT hBChE, 
WT pBChE and 
plant-derived 
cocaine hydrolase 
variants.  
Inhibition profiles 
against various 
anticholinesterase 
agents are shown. 
Each individual 
datapoint 
represents a mean 
± SEM. All IC50 s 
were compared 
by one-way 
ANOVA to WT 
hBChE.  
ns P > 0.05,  
* P ≤ 0.05,  
** P ≤ 0.01,  
*** P ≤ 0.001, 
**** P ≤ 0.0001. 
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Table 5. Inhibition of BTC hydrolysis by various anticholinesterase inhibitors. 
Log IC50 values ± S.E.M. of various anticholinesterase inhibitors vs. WT hBChE, WT 
pBChE, and plant-derived cocaine hydrolase variants of BChE. 
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Discussion 
 Here, we describe a broad biochemical analysis of plant-derived mutants of BChE 
designed for enhanced cocaine hydrolysis. First, we studied the oligomeric forms of 
BChE being expressed in plants. It was previously reported that nearly half of the BChE 
produced in stable transgenic plants is expressed as tetramers (Geyer et al., 2010a). We 
have shown here that transiently expressed pCocSH is primarily in the monomeric and 
dimeric forms (although small amounts of tetramers are also observed) (Figure 17). It 
could be speculated that this difference in the proportion of tetramers could be attributed 
to the extremely fast and high accumulation levels of proteins expressed via the transient 
expression method. Transient expression results in very rapid accumulation of high levels 
of foreign proteins in plants. It is possible that, similar to what was observed in transgenic 
goats expressing recombinant BChE in milk (Baldassarre et al., 2011), the ER protein 
folding machinery is overwhelmed leading to ER stress. ER stress can trigger a pathway 
known as the unfolded protein response (UPR) which is activated in response to the 
accumulation of unfolded or misfolded proteins in the ER (Howell, 2013). One way in 
which homeostasis is restored is through the ER-associated degradation (ERAD) of the 
misfolded proteins. Recent reports have shown that recombinant protein production in 
transgenic rice can activate the UPR (Iwata and Koizumi, 2012; Wakasa et al., 2013). It 
was very recently shown that transient magnICON-based expression of a potent 
immunogen, cholera toxin B subunit (CTB) in N. benthamiana caused ER stress and 
induced both the UPR and ERAD pathways (Hamorsky et al., 2015). 
 Interestingly, rather than an overall decrease in BChE yield, we observe that only 
the tetrameric form of BChE seems to be disproportionally lower compared to the 
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monomers and dimers. Collaborators observed that when BChE was transiently 
expressed in N. benthamiana with barley α-amylase SP and no C-terminal ER retention 
signal, primarily only the monomers were efficiently secreted to the apoplast of the plant 
cell (Schneider et al., 2014b). Other higher oligomeric forms were found to be deposited 
in the ER and it was hypothesized that the quality control systems at the ER-Golgi 
interface prevent release of the oligomeric BChE (Schneider et al., 2014b). One could 
imagine that the BChE is being targeted through the secretory pathway and once in the 
ER, the higher oligomeric forms such as tetramers remain to accumulate in the ER lumen. 
This accumulation could then lead to ER stress and activation of ERAD, while the 
monomeric forms remain protected by being efficiently secreted to the apoplastic space. 
Stably-produced BChE on the other hand could be expressed at a pace such that the ER is 
able to cope better with protein production, folding and accumulation. Though this is one 
hypothesis to explain our observations and requires further investigation, what is clear at 
this point is that a difference between the oligomeric state accumulated by pBChE is 
different depending on stable versus transient expression method used and it would be 
interesting to investigate a possible mechanism to explain this difference. 
 Regarding the kinetic parameters of these mutants, the catalytic activity of the 
cocaine hydrolase variants against both BTC and ATC deviate from the typical kinetic 
profiles WT BChE exhibits for these substrates. To create the variants, the WT BChE 
enzyme has been reengineered with the aid of molecular modeling, introducing mutations 
to the enzyme to redesign it to be more efficient at breaking down the cocaine, that could 
have led to altered kinetic behavior against other substrates (Pan et al., 2005; Gao et al., 
2006; Zheng et al., 2008; Yang et al., 2010; Zheng et al., 2010; Xue et al., 2011). 
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Alterations were made to residues at the bottom of the catalytic gorge near the π-cation 
binding site (A328) and to the peripheral anionic site (Y332) (Xie et al., 1999; Sun et al., 
2002a). The catalytic activity against (-)-cocaine was further improved through additional 
mutations to the oxyanion hole (A199) (Gao and Zhan, 2006), entrance to the gorge 
(S287) (Pan et al., 2005) and non-active site residues involved in hydrogen bonding 
interaction (F227) (Zheng et al., 2010). 
 The catalytic activity of mammalian-derived Variant 3 against BTC and ATC has 
been reported at lower substrate concentrations ranging to approximately 0.4mM which 
would be before the observed substrate inhibition we observe here and thus would have 
been undetected (Yang et al., 2010). BCh and its thiol derivative, BTC, although not 
biologically significant, is frequently used in in vitro assays, and alterations in WT 
kinetic behavior can offer insight into the impact of amino acid changes on enzyme 
behavior. The cocaine hydrolase variants exhibit rather apparent partial substrate 
inhibition against BTC. In a separate study, this substrate inhibition exhibited by BChE-
based cocaine hydrolases against BTC was also observed in a similar mutant 
A199A/S227A/S287G/A328W/Y332G which is a comparable cocaine hydrolase based 
on murine BChE developed for testing in mice (Geng et al., 2013). 
The catalytic efficiency of the plant-derived variant and its improvement over WT BChE 
is in agreement with reports of this same variant derived from other sources such as 
HEK-293F cells (Zhan et al., 2014). 
 In addition to monitoring the enzymes’ ability to hydrolyze substrates, their 
ability to bind inhibitors was also analyzed. Enhanced binding affinity to 
anticholinesterase agents is highly relevant as exogenous cholinesterases are a proven 
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prophylactic treatment to reducing OP-associated morbidity and mortality. Paraoxon, a 
metabolite of parathion commonly used in developing countries as an OP pesticide, can 
cause death. Variants 2 and 5 are particularly promising targets as seen by their enhanced 
affinity for paraoxon, neostigmine and iso-OMPA. Interestingly, Variant 3 and 4, the 
most well-characterized and most efficient BChE-based cocaine hydrolase mutants, 
display a more specific increased binding affinity toward paraoxon. Additionally, Variant 
4 has a higher ki indicating a more rapid reaction rate occurring between Variant 4 and 
paraoxon than WT BChE.  
 The biochemical characterization of the plant-derived cocaine hydrolases reported 
here offer not only a better understanding of an important source of an anti-cocaine 
treatment, but possible protection from the effects of a potent pesticide derivative and 
other anticholinesterase agents, adding to the practicality and versatility of the plant-
derived recombinant enzyme as a multivalent therapeutic. As new mutations are being 
found to establish even more efficient cocaine hydrolases, the results reported here point 
toward the importance of testing these enzymes for their additional potential as OP 
bioscavengers.  
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4 OLIGOMERIZATION STATES OF 
 PLANT-DERIVED COCAINE HYDROLASE VARIANTS OF BCHE  
 
Abstract 
 The cocaine super hydrolase, pCocSH, is a rationally-designed variant of human 
butyrylcholinesterase (A199S/F227A/S287G/A328W/Y332). The enzyme can be rapidly 
expressed at clinically relevant levels in plants; however, it is found primarily in an 
oligomeric form known to exhibit a relatively short circulatory half-life. An ideal 
treatment for cocaine addiction-related diseases would not only be catalytically efficient 
but also have sufficiently long biological half-life. Here we aimed to increase the 
proportion of the more stable tetrameric form of pCocSH. Our strategy was to co-express 
the enzyme with a peptide that contains the proline-rich attachment domain (PRAD) of 
the extracellular matrix protein Collagen Q. The peptide provides the necessary scaffold 
for the tetramerization of butyrylcholinesterase and we hypothesized that it will facilitate 
the tetramerization of pCocSH. Co-expression in plants of the enzyme and the peptide 
was achieved through combinatorial use of several transient expression vectors that are 
based on the genomes of a tobamovirus or a geminivirus and led to a substantial increase 
in the desired tetrameric form of the enzyme. 
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Introduction 
 Variants of the human serum enzyme butyrylcholinesterase (BChE) have been re-
engineered as cocaine hydrolases. These enzymes exhibit significantly improved catalytic 
activity against cocaine and are being investigated as a pharmacokinetic-based treatment 
for cocaine overdose and addiction. In order to be used as a therapy for addiction to 
prevent relapse in rehabilitated addicts, a reduced dosing regime of these enzymes is 
ideal. One strategy for decreasing the amount of enzyme needed is to increase the 
catalytic efficiency of the enzyme, which has been achieved (Zheng et al., 2008; Xue et 
al., 2013a; Xue et al., 2013b; Zhan et al., 2014). A second, complimentary strategy is to 
improve the enzyme’s circulatory stability. A longer mean residence time in circulation 
would mean less frequent doses of enzyme would be needed which would be ideal for the 
patient. 
 Pharmacokinetic parameters of BChE are determined by a combined effect of 
post-translational processes: glycosylation (Saxena et al., 1998) and oligomerization 
(Duysen et al., 2002). One reason that recombinant BChE is cleared faster than native 
plasma-derived BChE is the difference in glycosylation from producing the recombinant 
protein in various expression systems. WT hBChE has complex sialylated structures that 
have been a challenge to fully reproduce in recombinant expression systems, often 
leading to the exposure of foreign sugar motifs. When these recombinant-derived 
enzymes are delivered, the foreign glycans can lead to an immune response and rapid 
clearance by macrophages and other cells of the immune system ultimately ending in 
degradation of the enzyme in lysosomes. Concerning the oligomeric state of the enzyme, 
it is well known that the monomer and dimer forms of the enzyme have significantly 
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decreased circulatory half-life time compared to the tetrameric form (Duysen et al., 
2002), which is the form the human plasma-derived enzyme takes (Duysen et al., 2002). 
Unfortunately, recombinant BChE primarily accumulates in the less stable monomer and 
dimer forms, which are cleared faster through renal filtration (Blong et al., 1997; Saxena 
et al., 1998). Similarly, the circulatory half-life of acetylcholinesterase (AChE) is affected 
by its oligomeric state (Kronman et al., 1995) and presence of sialic acid (Velan et al., 
1993; Chitlaru et al., 2002). 
 Strategies have also been implemented to improve circulatory stability such as by 
the chemical addition of polyethylene glycol (PEG) derivatives. Large polymers of PEG 
(typically with a molecular mass ranging from 5 kDa to 20 kDa) can be chemically 
conjugated to the enzyme resulting in increased the size of the enzyme, and can aid in 
masking foreign glycans. PEGylation has been largely successful at improving half-life 
of recombinant BChE (Chilukuri et al., 2005; Chilukuri et al., 2008; Geyer et al., 2010b; 
Sun et al., 2013). PEGylation has also been found to trigger unwanted immune responses 
in humans (Sundy et al., 2007), although there have also been reports demonstrating lack 
of immunogenicity of PEGylated CHO-derived BChE in a macaque model (Rosenberg et 
al., 2010). Repeated administration of PEGylated BChE has also been shown to result in 
increased clearance, which also correlates with production of antibodies; and 
modification with particularly large PEGs (20 kDa) resulted in enhanced immunogenicity 
in mice (Chilukuri et al., 2005; Sundy et al., 2007; Chilukuri et al., 2008; Geyer et al., 
2010b; Ilyushin et al., 2013; Sun et al., 2013).  
 To address this challenge recombinant systems face, one strategy has been to 
include proline-rich peptides such as polyproline or the peptide rQ45 derived from the N-
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terminus of the collagen-tail protein, both of which promoted tetramerization of 
recombinant BChE produced in mammalian-based expression systems (Blong et al., 
1997; Altamirano and Lockridge, 1999a; Duysen et al., 2002; Gao and Brimijoin, 2004; 
Fang et al., 2014b). We hypothesize that this strategy can be implemented in a different 
eukaryotic expression system. 
 In the late 1990’s Bon et al. and Krejci et al. found that the N-terminus of the 
collagen-tail protein (COLQ gene), specifically a proline-rich portion, caused assembly 
of tetramers of AChE (Bon et al., 1997; Krejci et al., 1997). Two years later, Cibbey 
Varkey Altamirano and Oksana Lockridge amplified the cDNA encoding the N-terminal 
45 amino acids (QPTFINSVLPISAALPGLDQKKRGNHKACCLLMPPPPPLFPPPFF) 
of the rat collagen-tail protein and coined this “rQ45” (Altamirano and Lockridge, 
1999b). The 17-residue proline-rich attachment domain (PRAD) is underlined. This rQ45 
peptide was co-expressed with BChE to increase the proportion of tetramers in CHO cell-
derived BChE (Duysen et al., 2002).  
 Perhaps the most relevant part of rQ45 is the C-terminus of the peptide that 
contains two cysteine residues and a PRAD domain in the following amino acid 
sequence: CCLLMPPPPPLFPPPFF. This specific portion of the peptide was designated 
as PRAD1 by Pan et al. who studied this proline-rich portion of rQ45 in relation to BChE 
in computational models (Pan et al., 2009). It is still unclear how BChE subunits make 
the tetramer partly due to the lack of crystal structure of these orientations. The crystal 
structure of the WAT domain of AChE in complex with PRAD (PDB 1VZJ) offers clues 
to how this interaction occurs between BChE and PRAD (Dvir et al., 2004). The 3D 
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structural models by Pan et al., offer insight into the likely way in which BChE subunits 
associate with proline-rich peptides (Figure 22). 
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Figure 22. BChE in complex with a proline rich attachment domain (PRAD) modeled by 
(Pan et al., 2009). 
The green, orange, yellow and red colors each represent a BChE monomer. The cyan 
tube represents a PRAD chain. The BChE-PRAD complex is viewed from the top (A) or 
rotated 90° for a side view (B). The image in (C) shows the hydrogen bond interactions 
between tryptophans from the WAT domain located on the C-terminus of BChE and the 
carbonyl oxygens on PRAD. 
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 It is well established that the domain of BChE that is both sufficient and necessary 
for tetramerization is located at the C-terminus of the BChE monomer (Blong et al., 
1997; Altamirano and Lockridge, 1999a). The final 40 amino acids of the C-terminus of 
BChE comprise the tryptophan amphiphilic tetramerization (WAT) domain of the protein 
that facilitates tetramerization in the presence of proline-rich peptides (Blong et al., 1997; 
Altamirano and Lockridge, 1999b, a; Li et al., 2008b). Four parallel alpha helices of the 
WAT domains wrap around a single antiparallel PRAD helix (Pan et al., 2009). Deletion 
of this tetramerization domain results in exclusively monomer formation, and is essential 
for tetramerization to occur (Blong et al., 1997). Four C-termini of four BChE monomers 
form left-handed superhelices that stack around PRAD1 that is situated in the middle of 
the helices. The tetramerization domain of BChE has a cysteine at position 571 which can 
form disulfide bonds, though it has been shown that disulfide bonds are not essential for 
tetramer formation (Blong et al., 1997; Altamirano and Lockridge, 1999a). Interestingly, 
Pan et al. show that although not essential, these disulfide bonds influence the 
conformation of PRAD1 when associated with the tetramerization domain of BChE (Pan 
et al., 2009). If we designate four BChE monomers as I, II, III, and IV, according to Pan 
et al. (2009) the two cysteine residues on PRAD1 may form disulfide bonds with C571 of 
two of the BChE monomers (I and II). The remaining two monomers, III and IV, which 
cannot form disulfide bonds with PRAD1 may form a disulfide bond between each other. 
It is still unknown the order in which all of this occurs, or indeed if this is the case in 
vivo. Moreover, disulfide bond formation is not a pre-requisite for cholinesterase 
tetramerization as demonstrated with mutants of BChE in which C571were replaced by 
an alanine residue (Altamirano and Lockridge, 1999a, b). Further, in vitro studies 
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involving the incubation of purified recombinant BChE with polyproline peptides (which 
do not contain any cysteines) also increase the proportion of tetramers in vitro indicating 
again that tetramerization does not depend on disulfide bond formation (Larson et al., 
2014). The role of disulfide bridges in the quaternary structure of BChE seems that of 
stabilizing the noncovalent interactions between the four BChE monomers and the PRAD 
domain (Pan et al., 2009). 
 In order to utilize BChE-based cocaine hydrolases as anti-cocaine treatments, a 
source of the recombinant enzyme is needed which is affordable, easily scalable, and also 
exhibits desirably pharmacokinetic properties. Plants are a well-established production 
platform for the production of BChE, achieving the expression of enzymes that are 
kinetically equivalent to those derived from other source (Geyer et al., 2008; Geyer et al., 
2010a; Geyer et al., 2010b; Geyer et al., 2013; Larrimore et al., 2013). Excitingly, recent 
transgenic plants have been made with a humanized glycosylation pathway capable of 
generating plant-derived BChE with a glycosylation profile similar to that of plasma-
derived human BChE (Schneider et al., 2014a). Furthermore, BChE produced in stable 
transgenic plants is found as approximately 49% in the tetrameric form (Geyer et al., 
2010a). Interestingly, however, it is primarily in the monomeric and dimeric form when 
expressed using a transient expression method, which is often more desirable than stable 
expression due to the extremely rapid, high-level recombinant protein yields using 
transient expression. Here we investigated whether it is possible to increase the 
proportion of tetramers in a plant-derived cocaine hydrolase variant form of BChE 
through transient co-expression with the proline-rich peptide, rQ45.  
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 The magnICON TMV-based transient expression system was used extensively by 
us and many labs (Marillonnet et al., 2004; Gleba et al., 2005; Santi et al., 2006; Santi et 
al., 2008; Geyer et al., 2010a). However a multigene expression system based on 
tobamoviruses alone has proven difficult likely because of mechanisms limiting 
superinfection which prevents genotype competition within a cell (Gonzalez-Jara et al., 
2009). ICON Genetics developed several alternative strategies involving simultaneous 
infection by expression systems based on the genetic machineries of two different plant 
virus families, for example tobamoviruses and alphaflexiviruses (e.g. potato virus X) 
(Komarova et al., 2006; Gleba et al., 2007). For the transient co-expression of the two 
proteins, pCocSH and rQ45, we chose to use a geminivirus-based vector system either 
alone or in combination with the magnICON system. Geminiviruses that belong to the 
Mastrevirus genus have one of the most compact genomes among any virus group. Their 
genomes contain a single bidirectional promoter and two transcription units that encode 
for only four different proteins. Alternative splicing produces the Rep and RepA proteins 
that are important for replication of the viral DNA genome. Alternative translation start 
sites allow the expression of the movement and coat proteins (Morris-Krsinich et al., 
1985; Boulton et al., 1993). Two regulator regions were identified in the genomes of 
mastreviruses. The long intergenic region (LIR) functions as the aforementioned 
bidirectional promoter as well as containing a stem-loop structure that is nicked by Rep, 
which initiates rolling-circle replication from that position and ligates each genome copy 
when made (Saunders et al., 1991; Heyraud et al., 1993). The short intergenic region 
(SIR) contains relatively weak polyadenylation signals and provides the origin of the 
negative strand synthesis during the early phases of viral infection (Rizvi et al., 2015). 
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 Bean yellow dwarf virus (BeYDV) is one of only two Mastrevirus species that 
can infect dicots like N. benthamiana. The minimalist nature of the genetic machinery of 
BeYDV can be exploited for the production of large amount of recombinant proteins. 
During the past decade, the laboratory of Dr. Hugh Mason has developed progressively 
more versatile vector systems based on the genetic elements of BeYDV. At minimum, 
most of these vectors contain the complementary strand transcription unit (encoding 
Rep/RepA); the virion strand transcription unit was replaced by the expression cassette(s) 
of the gene(s) of interest, equipped with strong promoter(s) and terminator region(s) and 
the SIR separates the virion and complementary strands’ transcription units with two 
LIRs flanking the whole replicon (Zhang and Mason, 2006; Huang et al., 2009b; Chen et 
al., 2011; Phoolcharoen et al., 2011). Dual replicon BeYDV vectors with two expression 
cassettes linked in tandem, each flanked by an LIR, allows for the co-expression of two 
genes from a single vector (Huang et al., 2010). 
 For the transient co-expression of the two proteins, pCocSH and rQ45, we chose 
to use a geminivirus-based vector system either alone or in combination with the 
magnICON system. The ultimate goal of this study is to improve the oligomeric state of 
the plant-derived cocaine hydrolase enzyme toward the improvement of biological half-
life and development of a plant-derived anti-cocaine therapeutic. 
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Materials and Methods 
Construction of Expression Vectors 
 A vector was constructed containing tandemly arranged replicons, one containing 
the gene for pCocSH, the plant codon-optimized cocaine super hydrolase variant form of 
BChE (A199S/F227A/S287G/A328W/Y332) (Larrimore et al., 2013), the other encoding 
rQ45 (Duysen et al., 2002).  
 In the early 2000’s, the Mason lab group generated a high-level protein 
expression system based on the replication machinery elements of this virus (Mor et al., 
2003). Some elements that have been retained to promote high-level expression include 
the replication initiator protein (Rep), which is generated when an intron is spliced, and 
another protein that is the result of the unspliced mRNA called RepA. Rep has a nicking 
function that in turn releases DNA between long intergenic regions (LIR) that contains 
bidirectional promoter elements and a stem-loop structure needed for initiation of rolling-
circle replication. Individual DNA replicons, separated by distinct LIRs are then released 
and can then replicate independently in the case of a dual BeYDV replicon vector such as 
that described by Chen and coworkers (Chen et al., 2011). A similar construct was used 
in our study that also expresses the p19 tomato bushy stunt virus protein in order to 
suppress post-transcriptional gene silencing to further enhance expression of our genes of 
interest (Voinnet et al., 2003; Garabagi et al., 2012). pCocSH and rQ45 were both cloned 
into single replicon BeYDV vectors which can be co-infiltrated into the plant.  
 For this study, the endogenous endoplasmic reticulum (ER)-localizing signal 
peptide (SP) (MAVLNPMTLGIYLQLFFCSIVS) of rQ45 has been removed and in its 
place a barley-α -amylase ER-directing SP (MANKHLSLSLFLVLLGLSASLASG) is 
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used. The same barley-α-amylase SP was also fused to the 5’ end of pCocSH lacking an 
endogenous SP. Both genes were then cloned out of these single replicon vectors and into 
a single BeYDV-based plasmid vector with dual replicons. For cloning purposes, 5’ XbaI 
and 3’ SacI restriction sites were incorporated to flank each gene of interest. In order to 
make this dual replicon single vector, first both pCocSH and rQ45 were cloned separately 
each into the BeYDV-based expression vector, pBYR9a-MRtxG, by releasing the XbaI-
SacI fragment and ligating with either rQ45 or pCocSH flanked by the same sites to make 
pTM930 and pTM931 respectively (Huang et al., 2009b; Chen et al., 2011). All BeYDV-
based vectors used for cloning were generously provided by Dr. Hugh Mason and Andy 
Diamos. A three fragment ligation was then performed by digesting out an 1866 bp 
fragment of pBYR29a-MRtx with SacI and XhoI, a 2684 bp fragment from pTM931 
using AscI and SacI and finally using the 8489 bp backbone remaining after removing the 
801 bp AscI-XhoI fragment from pTM930 (Figure 23). The resulting dual replicon 
BeYDV vector, pTM934, was used for co-expression of the two separate genes, pCocSH 
and rQ45. The intermediate constructs pTM930 and pTM931 were also used to test co-
expression of the two proteins. DNA sequencing was performed for verification 
following each cloning step.  
 For description of cloning stable expression vector pGPTV-kan housing 
pCocSHER (pTM835) see the Materials and Methods section of Chapter 2. These stable 
lines expressing pCocSHER were then infiltrated with previously made construct 
rQ456xHIS/ER in ICON (pTM 648) for the transient expression of rQ456xHIS/ER. Briefly, the 
DNA encoding rQ45 (Duysen et al., 2002) was synthesized (Integrated Device 
Technology) and flanked with 5’ NcoI and 3’ SacI sites incorporated into the synthesized 
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gene. The NcoI and SacI restriction sites were used for downstream cloning into an ICON 
backbone digested with the same enzymes as previously described. 
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Figure 23. Cloning strategy for creating BeYDV-based (Gemini) dual replicon vector. 
Expression vector for two gene co-expression of pCocSH and rQ45. This improved 
vector backbone, created in the lab of Dr. Hugh Mason, utilizes the tobacco mosaic virus 
(TMV) 5’-UTR and incorporates an E. coli origin of replication (ori colE1) to increase 
replication and yield of the plasmid while in E. coli. Barley-α-amylase signal peptide 
(SP) was cloned to the 5’ end of each gene of interest. For further detail see Figure 25. 
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Plant Infiltration 
 The BeYDV vectors or ICON vectors harboring genes of interest were introduced 
into Agrobacteria tumefaciens strain GV3101 by electroporation. Transformed strains 
were screened via antibiotic selection as well as colony screen PCR and only positive 
colonies were used for downstream studies. Cultures were grown at 30ºC while shaking 
until mid-logarithmic phase, pelleted by centrifugation at 4,500 ×g for 20 minutes at 
room temperature then resuspended in 10 mM 2-(N-morpholino)ethanesulfonic acid 
(MES), 10 mM magnesium sulfate heptahydrate, pH 5.5 buffer. Plants were infected with 
vector-harboring A. tumefaciens at an optical density (O.D.)600 of either 0.1 or 0.4, by 
whole-plant vacuum infiltration in which entire WT N. benthamiana plants (not including 
root systems) are submerged in the Agrobacteria suspension (Larrimore et al., 2013; 
Leuzinger et al., 2013). 
DNA Extraction and PCR  
 Total DNA from infiltrated leaf tissue was extracted by the CTAB (cetyltrimethyl 
ammonium bromide) method (Wilke, 1996) followed by ethanol precipitation. This plant-
derived DNA was then used in 3 separate PCRs using various gene-specific primers 
(Table 6). The products of the PCRs were then run in a 0.9% agarose gel stained with 
SYBR® safe DNA gel stain (Invitrogen) and visualized under UV light. 
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Table 6. Primers used for confirmation of 
independent replicons produced in plants. 
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Protein Extraction and Purification 
 Three 0.2 g leaf samples from different plants were taken daily between 2 and 7 
days post infiltration (DPI) and individually lysed by FastPrep (MP Biomedicals) with a 
ceramic bead in cold 50 mM sodium phosphate buffer pH 8.0, and subsequently 
centrifuged at 4ºC for 20 minutes at 13,000 ×g to separate the total soluble protein (TSP) 
in the supernatant from the insoluble pellet. The three extract samples were then mixed in 
equal ratios to create a biological average for each DPI and were assayed per time point 
for enzymatic activity and presence of pCocSH.  
 Large-scale batches were prepared as described in Chapter 2. For affinity-based 
purification, dialyzed samples were subject to Concanavalin A (ConA) sepharose affinity 
chromatography as described in Chapter 2. 
Enzymatic Assay and Protein Quantification 
 A modified spectrophotometric-based Ellman assay was used to assess BChE 
activity with butyrylthiocholine iodide (BTC) (Sigma) as the substrate (1 mM) as 
described in Chapter 2. Estimation of the concentration of pCocSH was determined using 
the specific activity for this enzyme (36 U/mg pCocSH) as previously described in 
Chapter 2 by quantitative immunoblot assay (Larrimore et al., 2013). TSP levels were 
determined as described in Chapter 2 by the Bradford protein assay using Bio-Rad 
Protein Assay Reagent (Bio-Rad) and comparing to bovine serum albumin (BSA) 
standard. 
SDS-PAGE and Immunoblot Analysis  
 Plant extracts from a time course of pTM934 were prepared for denaturing SDS-
PAGE based on equal TSP content in standard 1× SDS sample buffer. Samples 
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containing equal amounts of TSP (2 µg TSP for immunoblot and 20 µg TSP for 
Coomassie staining per well) were resolved by SDS-PAGE in 8% polyacrylamide gels 
with 100 V until thorough separation was achieved. Gels were then either stained with 
Coomassie brilliant blue or transferred to nitrocellulose membrane for 25 V for 25 
minutes followed by immunodecoration with polyclonal rabbit anti-BChE antibodies 
(kindly provided by Dr. Oksana Lockridge) at a concentration of 1:5,000 followed by 
polyclonal goat anti-rabbit IgG-Horse Radish Peroxidase (1:10,000) secondary antibodies 
(Santa Cruz Biotechnology) followed by chemiluminescence analysis using western 
blotting luminol reagent (Santa Cruz Biotechnology). 
 For dot blot analysis, samples containing equal amount TSP were either all 
prepared with the reducing agent, dithiothreitol (DTT), and boiled at 95°C for 5 minutes 
if used in conjunction with anti-BChE antibodies, or samples were directly loaded (no 
boiling or sample buffer addition) to activated polyvinylidene fluoride (PVDF) 
membrane. The membrane was immunodecorated with either rabbit polyclonal anti-
hBChE antibodies (1:5,000) or rabbit polyclonal anti-rQ45 antibodies (1:1,000) (Santa 
Cruz Biotechnology, catalogue no. sc 133472) with goat anti-rabbit IgG-Horse Radish 
Peroxidase secondary antibodies (Santa Cruz Biotechnology) followed by 
chemiluminescence analysis using western blotting luminol reagent (Santa Cruz 
Biotechnology). 
 For anti-rQ45 SDS-PAGE and western blot analysis, a 5.2 kDa synthetic 49 
amino acid long peptide similar to rQ45 based on the human ColQ protein designated 
rQ49 (SQPTFINSVLPISAALPSLDQKKRGGHKACCLLTPPPPPLFPPPFFRGG) was 
solubilized in water (LifeTein). All samples were prepared in standard 1× SDS sample 
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buffer and boiled at 95ºC for 3 minutes. Samples were resolved by denaturing SDS-
PAGE in a 22% polyacrylamide gel subject to 100 V for 80 minutes. Proteins were then 
transferred to PVDF membrane using 15 V for 12 minutes under discontinuous buffer 
conditions. During transfer the bottom blot pad next to membrane was soaked in standard 
transfer buffer (48 mM Tris, 39 mM glycine) containing 20% methanol to facilitate 
protein binding to the membrane, while the blot pad next to gel was soaked in the 
standard transfer buffer (48 mM Tris, 39 mM glycine) containing 0.1% SDS with no 
methanol to facilitate the movement of the small peptide through the gel. Upon transfer 
the same protocol was followed as above using the rabbit polyclonal anti-rQ45 antibodies 
at a concentration of 1:200 (Santa Cruz Biotechnology).  
In Vitro Tetramerization 
 Highly purified pCocSH (no rQ45 co-expression) was concentrated (5.5 mg/mL) 
and incubated in vitro for 1.5 hours at room temperature with 100 µM 50-mer Poly-L-
proline peptides from Sigma Alderich (catalogue Number P2254) having an average 
molecular weight of 6200 Da (Larson et al., 2014).  
Size Exclusion HPLC 
 ConA purified pCocSH with or without co-expression of rQ45, along with 
molecular standards of known sizes, were analyzed by SEC-HPLC and subject to 
fractionation as described in Chapter 3. Those fractions containing BChE were then 
subject to native gel (nondenaturing PAGE) analysis. 
Nondenaturing PAGE and Activity Gel Staining 
 Samples of purified WT human plasma-derived BChE and ConA or HPLC 
purified pCocSH co-expressed with or without rQ45 were prepared in non-denaturing 
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sample buffer (0.0625M Tris pH 6.8, 10% glycerol and 0.01% bromophenol blue) and 
resolved by gel electrophoresis under non-denaturing conditions. Polyacrylamide 10% 
gels were run with 100 V for 16 hours at 4°C. Gels were then stained by the method of 
Karnovsky and Roots as previously described using BTC as the enzymatic substrate (Mor 
et al., 2001; Geyer et al., 2010a). 
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Results 
Co-Expression of Two Recombinant Proteins, pCocSH and rQ45, in Plants 
 The goal of our study was to determine if the proportion of tetramers in 
transiently-expressed plant-derived BChE could be increased through co-expression with 
a proline-rich peptide, rQ45. There are two major limitations of the tobamovirus-based 
magnICON system. First, the TMV replicon is size-limited and can accommodate only 
three open reading frames including the two encoding the RNA-dependent RNA 
polymerase (RdRp) and the movement protein (MP) (Roy et al., 2010). The second 
limitation is viral exclusion, which prevents co-replication of two different TMV-based 
replicons (Giritch et al., 2006). Our approach was to co-express the two proteins in plants 
using a replicon BeYDV-based system. An important benefit of the BeYDV system is 
that, unlike the TMV-based magnICON, two separate replicons can be replicating in the 
same cell. Alternatively, one foreign gene can be expressed from a magnICON vector 
while the other is expressed from a BeYDV vector. To test the first of these expression 
tactics, we created two separate BeYDV vectors encoding for pCocSH (pTM931) and 
rQ45 (pTM930). These were used together for agroinfiltration into N. benthamiana and 
the proportion of tetramers in concentrated ConA eluates was characterized by 
nondenaturing PAGE and SEC-HPLC. Qualitatively, pCocSH with rQ45 resulted in a 
larger amount of higher molecular mass bands compared to pCocSH without rQ45 which 
can be seen in darker activity staining in the higher portion of the native gel and 
coinciding with the size of WT hBChE tetramers (Figure 24a). SEC-HPLC was then used 
to enable more precise quantitation of these various species. The presence of rQ45 
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correlated with an increase in the proportion of BChE eluting from the column at the 
expected elution time of tetramers relative to internal standards (Figure 24b). 
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Figure 24. Tetramerization of 
transiently expressed pCocSH co-
expressed with rQ45 on separate 
Gemini vectors. 
pCocSH expressed alone (-) or co-
expressed with rQ45 (+) in separate 
BeYDV-based expression vectors was 
subject to ConA purification and 
following stepwise elution, eluates 2, 
3, and 4 (E2, E3, and E4) were 
concentrated and equal amounts of 
BChE based on activity were resolved 
by native PAGE and stained for 
BChE activity (A) with human 
plasma-derived BChE (hBChE) 
included as a standard for size 
comparison and uninfiltrated WT N. 
benthamiana included as a negative 
control (c). Size-exclusion HPLC 
analysis (BTOP) and enzymatic activity 
of fractions collected during SEC-
HPLC analysis (BBOTTOM) of ConA 
purified preparations of pCocSH with 
(maroon) or without (grey) co-
expression of the proline-rich peptide 
rQ45 with each gene being housed on 
separate single replicon BeYDV-
based vectors. Oligomeric states are 
distinguished as tetramer (4°), dimer 
(2°), and monomer (1°). Blue dextran 
(2000kDa), β amylase (200kDa), and 
albumin (66kDa) were included as 
standards, and respective elution  
peaks are indicated with arrows.  
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 To test the second expression tactic, A. tumefaciens harboring either pCocSH in 
ICON (pTM949 as described in Chapter 2) by itself, or mixed with A. tumefaciens 
harboring pTM930 (rQ45) were infiltrated into WT N. benthamiana. When agrobacteria 
harboring pTM949 by itself were infiltrated into plants, pCocSH accumulated to high 
levels of almost 400 mg BChE/kg leaf (and even higher using other infiltration 
conditions, Table 7). However, the accumulation levels of pCocSH upon simultaneous 
co-infiltration into plants precipitously dropped to less than 4% of the accumulation level 
noted in plants infiltrated with the pCocSH-expressing magnICON vector (Table 7).  
 Considering the typical expression kinetics supported by the BeYDV vectors, 
which peaks four to seven days prior to peak magnICON-driven accumulation of 
recombinant proteins (Chen et al., 2011), we hypothesized that the timing of the two very 
different viral replication mechanisms between the ICON and Gemini constructs could 
have played a role in the decrease in expression. To test this possibility, we devised a 
staggered infiltration regimen. pCocSH-magnICON vector was delivered first by 
infiltration. The agroinfiltrated plants were then returned to the growth chamber for 5 
days at which time they were infiltrated again, this time with BeYDV-rQ45 vector. They 
were returned to the growth chamber and harvested at the peak day for both constructs 
(10 DPI for pCocSH in ICON and 5 DPI for rQ45 in Gemini). Using this method 
expression levels reached around 940 mg pCocSH/kg leaf (Table 7), although the leaf 
material was quite desiccated by the end of the experiment. A large-scale infiltration was 
done using the same staggered strategy with vacuum style infiltration. There did not, 
however, appear to be any change in the proportion of tetrameric BChE in this extraction 
(data not shown). The experiment bears repeating, however, because although the 
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presence of rQ45 was confirmed it is difficult to quantify expression levels of the peptide. 
Furthermore, the plants had a very desiccated, dark, wilted appearance lacking biomass 
by the day of extraction. Refining the day of infiltration/extraction could also be further 
refined if this is to be explored further. This method can be cumbersome, however, due to 
the different bacteria needed and two separate infiltrations required. If both genes could 
be housed on a single vector and thus single bacteria culture grown infiltrated, then that 
would be most convenient for the co-expression of two genes in plants. 
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Table 7. Average pCocSH accumulation in plants over time 
with and without rQ45 co-expression. 
Plants were infiltrated with separate bacteria cultures harboring 
either pTM949 (pCocSH in ICON) or additionally with pTM 
930 (rQ45 in Gemini). Plants were either infiltrated with both 
contructs at the same time (co-infiltrated) or on separate days 
(staggered). BChE (mg BChE/kg fresh weight leaf material) 
shown at indicated days post infiltration (DPI). Under the 
staggered regime samples were analyzed at 10 DPI for 
pTM949 that coincided with 5 DPI for pTM930. 
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 To fully take advantage of the versatility of the BeYDV-based expression system, 
we turned to a newly engineered binary vector that introduces a single T-DNA species 
harboring three copies of LIR sequences allowing two independently replicating 
replicons to emerge. This vector, pTM934 was constructed to include two expression 
cassettes containing both genes of interest, necessary viral replication machinery, and p19 
(Figure 25a). Once transferred by the Agrobacteria into the plant cell, the replicons 
harboring their respective genes of interest escape from the T-DNA and can replicate 
independently in the same plant cell (Figure 25b). To confirm this, the following PCR 
scheme was devised (Figure 25c). If both replicons are present in the plant cells, then 
divergent-facing BChE-specific primers (Set 1) would be expected to yield a 2332 bp 
fragment and divergent-facing rQ45 replicon-specific primers (Set 2) should yield a 1579 
bp fragment, both of which were observed (Figure 25). Under the specified PCR 
conditions, similar fragments are not expected to be amplified from either the linear T-
DNA, or from the parental binary vector (Figure 25a). When using a properly facing set 
of a forward BChE-specific and reverse rQ45-specific primer (Set 3) amplification based 
on the linear T-DNA or the binary vector templates is theoretically possible, but was 
nonetheless not observed. These results indicate that both linear T-DNA molecules and 
parental binary vectors are present at very low level in the infiltrated cells. However, the 
expected free replicons are present at very high levels within the plant cells, suggesting 
an efficient Rep-dependent escape of the replicons and their subsequent replication. After 
confirming the presence of replicons harboring the pCocSH and rQ45 genes, we next 
determined if pCocSH was successfully being expressed in the plant. 
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Figure 25. Dual BeYDV replicon vector for co-expression of pCocSH and rQ45. 
Schematic representation of the T-DNA cassette (A) flanked by left border (LB) and 
right border (RB) within the single BeYDV-based expression vector that contains 
two replicons in tandem for the co-expression of two genes. Both expression 
cassettes use a cauliflower mosaic virus 35S promoter (35S) and tobacco mosaic 
virus (TMV) extension (Ext) 3’ region. This construct also housed a silencing 
suppressor (p19) flanked by a nopaline synthase promoter (nos) and nos 3’ UTR (3’). 
Introns are indicated (I). The replicons are flanked by long intergenic regions (LIR) 
and each has a short intergenic region (SIR). Signal peptides (SP) are fused to both 
pCocSH and rQ45. The replicon housing pCocSH has a C1/C2 deletion (C) to allow 
transcription of C1/C2 to be solely derived from the other replicon. Two separate, 
independently replicating single stranded DNA replicons are released (B) which 
amplify by rolling circle replication in the cytoplasm of the plant cell. Presence of 
these independent DNA replicons was confirmed by three separate PCRs (C) 
performed on total DNA extracted from the infiltrated plant cell (gDNA) or on the 
Eschericia coli-derived BeYDV parental vector (plasmid) containing the T-DNA 
cassette (pTM934). Negative controls for each reaction mixture were included which 
substituted template DNA for water. Binding sites and directionality of primers used 
in the study are indicated by black arrows (arrows not drawn to scale).  
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High-level Expression of Plant-Derived Cocaine Hydrolase Co-Expressed with 
Tetramerization-Inducing Peptide 
 Using a dual replicon BeYDV vector, pCocSH accumulated over time in plants, 
with peak expression occurring at around 6 days post inoculation (DPI) (Figure 26). 
Beginning at about 6 DPI, the leaves of the plants were very desiccated, wilted, and grey 
in color (data not shown). The presence of the active enzyme was confirmed using an 
enzymatic assay and over 150 mg pCocSH per kg leaf (>1%TSP) was achieved (Figure 
26a). Accumulation of pCocSH relative to other plant proteins was visible in Coomassie 
staining (Figure 26b). Further confirmation of the expression of pCocSH was achieved by 
western blot analysis using BChE-specific antibodies (Figure 26c). 
 To confirm the expression of rQ45, a dot blot was performed and presence of the 
protein was confirmed using anti-rQ45 antibodies in plant samples infiltrated with the 
gene encoding rQ45 as compared to uninfiltrated WT N. benthamiana (Figure 27). 
Various strategies for confirming the presence of rQ45 via SDSPAGE and western blot 
analysis were performed, however it was difficult to detect plant-derived rQ45 using this 
method and this method can perhaps be further optimized to be able to detect the small 
peptide via SDS-PAGE and western blot (Figure 28). 
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Figure 26. Expression of pCocSH in plants over time using dual BeYDV replicon vector.  
Soluble proteins were extracted from leaves 2-7 days post infiltration with A. tumefaciens 
harboring pTM934. Each day represents a biological average of the mixture of protein 
extracts from three different plants. Concentration of pCocSH relative to the leaf fresh 
weight (measured as previously described in Chapter 2 Materials and Methods) is shown 
on the left y axis and relative to the TSP content is shown on the right y axis (A). 
Accumulation of pCocSH relative to other plant proteins was visualized by Coomassie 
blue staining (B) with arrows indicating the expected positions of the protein bands of 
pCocSH. Presence of pCocSH protein was further confirmed by immunoblot analysis 
using polyclonal BChE specific antibodies (C). Gels were loaded based on equal TSP 
concentration as determined by the Bradford assay and uninfiltrated WT N. benthamia (c) 
was included as a control. 
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Figure 27. Immunoblot detection of rQ45 and 
pCocSH. 
Dot-blot hybridization using BChE specific (top 
panel) or rQ45-specific (bottom panel) polyclonal 
antibodies. Equal total soluble protein was loaded 
(5 µg) in equal volume and each sample was loaded 
in replicate. Samples used in conjunction with Anti-
BChE antibody treatment were prepared in 0.1 M 
DTT with boiling, while samples used with anti-
rQ45 antibodies were loaded directly onto the 
PVDF membrane under non-denaturing conditions. 
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Figure 28. SDS-PAGE of rQ45. 
SDS-PAGE of varying concentrations of the synthetically produced peptide, 
rQ49, run alongside maximum volume loading of ammonium sulfate 
clarified/concentrated pCocSH co-expressed with rQ45 protein (via pTM934) and 
uninfiltrated WT N. benthamiana (c). Proteins were separated in a 22% gel then 
transferred to PVDF membrane and subject to immunoblot analysis with anti-
rQ45 antibodies (A). An equivalently loaded gel was run under the same 
conditions the stained with Coomassie blue stain (B). The gel after transfer was 
stained with Coomassie blue stain to ensure efficient transfer of low molecular 
weight bands (C).  
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Co-Expression of pCocSH with Proline-Rich Peptide Promotes Tetramer Formation in 
Plants  
 After expression of both proteins were confirmed using the dual replicon single 
vector (pTM934), influence in oligomeric state was investigated using nondenaturing gel 
electrophoresis followed by gel staining based on enzymatic activity. Samples co-
expressing rQ45 had a visible increase in tetrameric-sized BChE when using the WT 
hBChE for size comparison (Figure 29). In order to separate these oligomeric states in a 
complementary fashion, these purified preparations of pCocSH with and without rQ45 
were separated by SEC-HPLC and the proportion of tetrameric BChE was larger in 
samples co-expressing rQ45 (Figure 30). Tetrameric, dimeric and monomeric fractions 
were collected, concentrated, and run on a native polyacrylamide gel, which was then 
stained for BChE activity. For pCocSH alone, the proportion of BChE present in the 
fractions correlating to tetramers was very small compared to plants that supported the 
accumulation of both enzyme and the rQ45 peptide (Figure 30c). 
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Figure 29. Native gel analysis of oligomeric states of 
pCocSH co-expressed with rQ45 using a dual replicon 
BeYDV vector (pTM934). 
Oligomeric states of p pCocSH alone (-rQ45) or co-
expressed with rQ45 (+rQ45) separated by native 10% 
PAGE and stained for BChE activity. hBChE was included 
as a standard for size comparison. 
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Figure 30. Tetramerization of transiently expressed pCocSH co-expressed 
with rQ45 on a dual replicon BeYDV vector. 
Size-exclusion HPLC analysis (A) and enzymatic activity of fractions 
collected during SEC-HPLC analysis (B) of equal injection amounts 
based on activity of ConA purified preparations of pCocSH with (maroon) 
or without (grey) co-expression of the proline-rich peptide rQ45. 
Oligomeric states are distinguished as tetramer (4°), dimer (2°), and 
monomer (1°). Blue dextran (2000 kDa), β amylase (200 kDa), albumin 
(66 kDa) and carbonic anhydrase (29 kDa) were included as standards. 
Eluted fractions 15, 17 and 19 were concentrated and resolved by native 
PAGE and stained for BChE activity (C) with human plasma-derived 
BChE (hBChE) included as a standard for size comparison and 
uninfiltrated WT N. benthamiana included as a negative control (c). 
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Tetramerization of Purified, Concentrated pCocSH not Promoted in Vitro by Incubation 
with Polyproline Peptides  
 Other groups have used similar yet slightly different strategies to increase the 
proportion of tetrameric BChE. Recently a group has succeeded in doing so completely in 
vitro by incubating purified concentrated BChE with polyproline peptides (Larson et al., 
2014). Using our purified material their procedures were repeated; however, the 
oligomeric form of pCocSH did not change in any of the various attempts. One 
representative experiment is shown (Figure 31).  
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Figure 31. SEC-HPLC analysis of an in vitro tetramerization assay. 
SE HPLC analysis of pCocSH with (red) or without (black) incubation with poly-L-
proline peptides. The in vitro tetramerization assay was performed using 100 µM of 
50-mer Poly-L-proline from Sigma Alderich. Peptides were solubilized in water 
and added to highly purified, concentrated pCocSH (5.5 mg/mL) and allowed to 
incubate for 1.5 hours at room temperature. 
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Oligomeric State of pCocSHER Derived from Stable Transgenic Plants and Effects of 
Transient Co-Expression with rQ456xHIS/ER. 
 Stable transgenic plants expressing pCocSHER naturally show a relatively large 
proportion of tetramer without co-expression of any proline-rich peptides (Figure 32). In 
order to determine if this could be further improved by co-expressing rQ45 we transiently 
expressed rQ456xHIS/ER using stable transgenic plants expressing pCocSHER. Since these 
were stably expressing pCocSHER, a previously constructed ICON vector harboring 
rQ456xHIS/ER was used. Both proteins are targeted to the secretory pathway and contain C-
terminal ER retention signals. Interestingly, no change to oligomeric state was observed 
when transiently expressing rQ456xHIS/ER via ICON in stable transgenic plants expressing 
pCocSHER (Figure 33). Recently, stable lines expressing pCocSH with no C-terminal 
modifications have been created and it would be interesting to infiltrate these plants with 
rQ45 with no C-terminal modification to see if there is any affect.  
 
  
128 
    
Figure 32. Tetramerization of pCocSHER expressed in stable 
transgenic plants. 
Size-exclusion HPLC analysis displaying absorbance (A)280 as 
arbitrary units (top) and enzymatic activity of fractions collected 
during SEC-HPLC analysis (bottom) of ConA purified preparations of 
pCocSHER expressed in stable transgenic plants. No proline rich 
peptides were used. 
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Figure 33. Tetramerization of pCocSHER expressed in stable 
transgenic plants with transient co-expression of rQ45. 
Size-exclusion HPLC analysis (top) and enzymatic activity of 
fractions collected during SEC-HPLC analysis (bottom) of ConA 
purified preparations of pCocSHER expressed in stable transgenic 
plants with (maroon) or without (grey) co-expression of the proline-
rich peptide rQ45HIS/ER using the magnICON transient expression 
system. 
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Discussion 
 In an effort to improve the pharmacokinetic properties of a plant-derived cocaine 
hydrolase enzyme, we sought to determine whether co-expression with a proline-rich 
peptide would increase the proportion of tetramers, which are a desirable configuration 
due to its increased circulatory stability compared to monomers and dimers. Using a dual 
replicon BeYDV-based expression vector, pCocSH was successfully expressed in N. 
benthamiana plants and pCocSH accumulated over time (Figure 26). The characteristic 
double bands of BChE observed between 69-75 kDa were visible in the western blot of 
these samples as well, corresponding to the anticipated hybrid glycan structure of the 
enzyme, which has 9 N-linked glycosylation sites (Geyer et al., 2010a; Geyer et al., 
2010b). No major degradation product was seen at the most common size of 55 kDa 
which is the result of an N-terminal truncation which has been reported in plant-derived 
WT BChE and observed in our own lab as well with other constructs (Schneider et al., 
2014b).  
 Although it is difficult to detect rQ45 via SDS-PAGE, it was detectable in plant 
samples expressing rQ45 but not in those only expressing BChE or uninfiltrated control 
plants. Although rQ45 extracted from plant material was not confirmed via SDS-PAGE 
(Figure 28) it is more likely that it is present but not being detected efficiently based on 
the dot blot analysis (Figure 27). Furthermore, no studies that used rQ45 have ever 
confirmed the expression of the recombinant rQ45 protein to date. Part of the difficulty in 
detecting in this manner is likely due to both the nature of the peptide and the sensitivity 
of the antibody detecting the protein. The peptide has characteristics which make is 
challenging to work with using SDS-PAGE including the fact that it is extremely small, 
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about 4.9 kDa with a pI of 9.4 and is 62% hydrophobic. If transfer conditions are not 
optimized or it does not efficiently stay bound to the membrane, it will be challenging to 
detect. Furthermore the only time a band at the appropriate size was detected was using 
the highly purified synthetically produced peptide rQ49 at a concentration of 12.5 µg 
using an antibody dilution of 1:200. It cannot be concluded yet whether the plant-derived 
samples are showing a true negative, or more likely based on the dot blot, are simply 
below the level of detection using this current method. This strategy could be further 
optimized; however, antibody cost may be a factor when using such high concentrations. 
At this stage even confirmation by dot blot (Figure 27) would be the first study to address 
the presence of the recombinant rQ45 used in conjunction with recombinant BChE. 
 When expressed alone transiently in plants, pCocSH primarily forms dimers and 
monomers, with some, although few, tetramers, which is consistent with other 
recombinant BChE expression systems (Blong et al., 1997; Duysen et al., 2002; Ilyushin 
et al., 2013). When rQ45 was expressed in plants along with BChE either on individual 
BeYDV-based single replicon vectors (pTM930 and pTM931), or both on a single, dual-
replicon vector (pTM934), an increase in tetrameric BChE was observed. The use of the 
single vector with dual replicons is a particularly attractive approach because only one 
transformed strain of Agrobacteria must be grown and used to infiltrate plants. 
Furthermore, both genes being on the same transfer DNA segment delivers both genes to 
the same cells more efficiently than when using two separate strains of Agrobacteria 
harboring separate T-DNA regions that must both be transferred to the same plant cells. 
This becomes even more problematic due to the lack of cell-to-cell movement of 
replicons in current Gemini-based systems. It is likely that the two proteins, pCocSH and 
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rQ45, first interact inside the plant cell when transiently co-expressing both proteins, 
however studies would have to confirm this experimentally. Recent studies have shown 
that a cellular environment is not necessary in order for proline-rich peptide to become 
associated with BChE, as this was accomplished in vitro using purified BChE and 
polyproline peptides (Larson et al., 2014). When the in vitro experiments were repeated 
using purified concentrated pCocSH, we observed no increase in tetramers (Figure 31). 
One representative experiment is shown in this Chapter, however multiple variations as 
described by Larson et al. were replicated precisely as described including at higher 
temperatures (37°C), varying incubation times (including a 35 day incubation), and 
varying pCocSH concentrations. Similar experiments were conducted replacing poly-
proline peptides with lamellipodin-derived peptides (data not shown), which also did not 
result in increased tetramer formation. It is possible that, similar to what was observed in 
unpurified mammalian cell culture media, proteases released during cellular lysis cleaved 
off the C-terminal tail of pBChE, which is known to be a target of protease cleavage 
(Blong et al., 1997; Larson et al., 2014). The C-terminal tail of BChE contains the 
tetramerization domain that is necessary for the formation of tetramers and is where 
proline-rich attachment domains interact with BChE (Blong et al., 1997; Altamirano and 
Lockridge, 1999a; Pan et al., 2009). Further studies will are needed to determine if this 
was the case here. It does, however, suggest that co-expression with rQ45 is an 
advantageous strategy for plant-derived BChE. 
 A rational design alternative to using proline-rich peptides was recently reported 
in which designed amino acid mutants of BChE led to an increase of half-life by about 6 
hours in rats (Fang et al., 2014b). Although the additional mutations did not significantly 
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alter the catalytic efficiency against (-)-cocaine, alterations to affinity toward other 
substrates of the enzyme such as ACh were not tested. Additional mutations could 
increase higher oligomeric structures, but if they also result in increased catalytic 
efficiency against the neurotransmitter acetylcholine, then that would have negative 
physiological consequences. Using a proline-rich peptide such as rQ45 would not involve 
further altering the primary amino acid sequence of pCocSH, yet could also increase the 
higher oligomeric forms of the enzyme. Furthermore, this unique system involving a 
single dual-replicon BeYDV-based vector offers non-competitive, independent 
expression of two different proteins with the additional advantage of originating from a 
single vector. Use of a single vector to deliver two genes likely increases the likelihood of 
both proteins being produced in the same plant cell (and consequently interacting) while 
decreasing the need for growing multiple bacterial cultures harboring different expression 
vectors, which in turn can reduce cost and time. 
 The studies reported here show that the oligomeric state of a therapeutically 
relevant plant-derived cocaine hydrolase can be enhanced. Use of a single vector dual 
replicon transient expression platform successfully optimized co-expression of two 
recombinant proteins in plants while providing fast, high-level production of the 
recombinant enzyme. Future studies discussed in Chapter 5 investigate the 
pharmacokinetic parameters of these plant-derived cocaine hydrolase tetramers in vivo. 
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5 PROTECTION AND REVERSAL OF COCAINE-INDUCED TOXICITY  
IN PCOCSH-TREATED MICE  
 
Abstract 
 The protein pCocSH is a plant-produced variant of butyrylcholinesterase (BChE, 
A199S/F227A/S287G/A328W/Y332G) that was rationally designed to improve the 
enzyme’s catalytic efficiency toward (-)-cocaine. The enzyme was produced in Nicotiana 
benthamiana plants, purified to homogeneity and was tested in vivo for its ability to 
protect mice from cocaine overdose and reverse cocaine-induced toxicity. These studies 
revealed that pCocSH administered at levels as low as 3 mg/kg can fully protect mice 
from an otherwise lethal dose (LD100) of cocaine from subsequent death, and rapidly 
reverse toxicity symptoms. The potential of this commercially viable production system 
to provide an effective biologic to counteract cocaine toxicity and addiction is discussed. 
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Introduction 
 One therapeutic approach to counteract the toxic and addictive psychoactive 
effects of cocaine is to accelerate the drug’s metabolism producing biologically inactive 
products using cocaine-hydrolyzing enzymes (Zheng and Zhan, 2011). 
Butyrylcholinesterase is a human serum enzyme that is responsible for the inactivation of 
cocaine in vivo, resulting in the transient nature of cocaine induced euphoria (Stewart et 
al., 1977; Inaba et al., 1978; Stewart et al., 1979). However, the limited hydrolytic 
capacity of this promiscuous enzyme toward (-)-cocaine, the psychoactive enantiomer of 
the drug, does not allow the enzyme to remove it rapidly enough from the human body in 
situations of overdose. Variants of BChE were rationally-designed using molecular 
dynamics and modeling based on the atomically-resolved structure of the enzyme (PDB 
1P0P) resulting in mutants with improved catalytic efficiency against (-)-cocaine 
compared to the wild-type BChE enzyme (Sun et al., 2002a; Sun et al., 2002b; Pan et al., 
2005; Brimijoin et al., 2008; Zheng et al., 2008; Yang et al., 2010; Carroll et al., 2011; 
Xue et al., 2011; Anker et al., 2012; Xue et al., 2013a; Xue et al., 2013b; Zheng et al., 
2014). In particular, the pentavalent mutant variant of BChE 
(A199S/F227A/S287G/A328W/Y332G) was shown to be extremely effective as a 
cocaine hydrolase both in vitro and in vivo (Zheng et al., 2008; Xue et al., 2013a). The 
recombinant BChE-based cocaine hydrolase enzymes (A199S/S287G/A328W/Y332G) 
and (A199S/F227A/S287G/A328W/Y332G) derived from mammalian expression 
systems have been shown to fully protect mice and rats from respective lethal dose of 
cocaine (180 mg/kg and 100 mg/kg) (Brimijoin et al., 2008; Zheng et al., 2008; Xue et 
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al., 2011). These enzymes were also able to rescue rats after the onset of cocaine-induced 
convulsions (Brimijoin et al., 2008).  
 We have recently provided evidence that this BChE variant can be expressed in 
plants at commercially viable levels, and exhibits a > 2000 fold improved catalytic 
efficiency against cocaine as compared to the wild type enzyme (Chapter 3) (Larrimore et 
al., 2013). The plant-derived enzyme, which we named pCocSH (Plant-derived COCaine 
SuperHydrolase), proved to be enzymatically similar to what was previously 
demonstrated for the low-scaled, mammalian-cell produced enzyme (Zheng et al., 2008; 
Zheng and Zhan, 2011). Here we test our hypothesis that pCocSH would offer effective 
protection against acute cocaine and test the hypothesis in a mouse model. 
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Materials and Methods 
Protein Expression and Purification  
 The pCocSH enzyme was transiently expressed in wild-type (WT) N. 
benthamiana plants using the magnICON vector system based on deconstructed tobacco 
mosaic virus and extracted as was described in previous chapters. All pCocSH prepared 
for animal studies in Chapter 5 was derived from plasmid pTM783 and has a C-terminal 
6x histidine tag, however this tag was of no particular importance to this study and will 
not be further designated in this chapter (it will be designated as pCocSH for simplicity 
rather than pCocSH6xHis). The pCocSH enzyme was extracted from the plant tissue as 
described in previous chapters. The preparation was then subject to ConA purification as 
previously described and was eluted with 5 stepwise increasing concentrations of methyl-
α-D-mannopyranoside (0.05 M, 0.1 M, 0.2 M, 0.5 M, and 1 M). Purity of the various 
eluates was tested by SDS-PAGE (data not shown) as previously described. All 5 eluates 
showed similar degrees of purity and were therefore pooled, concentrated, and dialyzed 
against 20mM sodium phosphate buffer, pH 7.5 to remove all sugar and salt. This sample 
(ConA [E1-E5], 86 mg pCocSH) was then subject to final polishing using batch 
procainamide affinity chromatography to remove any remaining contaminants. The 
pCocSH protein was bound to procainamide agarose gel custom affinity resin (Sigma, 
catalogue no. P2240). The use of procainamide as an affinity ligand was developed in the 
lab of Bert N. La Du by Karen Mesch (Lockridge and La Du, 1978). The pCocSH protein 
was eluted with stepwise increasing concentration of salt followed by salt along with 
procainamide HCl as follows: E1=0.05 M NaCl, E2=0.5 M NaCl, E3= 1 M NaCl, E4=1 
M NaCl + 0.2 M Procainamide HCl, E5=1 M NaCl + 0.3 M Procainamide HCl). 
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Procainamide is a specific, reversible inhibitor of cholinesterase and it is therefore 
important to ensure thorough dialysis and removal of all procainamide before 
downstream analysis and use. The eluates were dialyzed against 2 × 4 L of 1× PBS, pH 
7.4 and eluates 3, 4 and 5 were pooled and concentrated (procainamide [E3-E5], 75 mg 
pCocSH). Based on SEC-HPLC, silver staining and BChE-specific western blot (Figure 
34), this yielded pure material that had a specific activity of 35.9 U/mg.  
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Figure 34. Purification of pCocSH for animal studies.  
SEC-HPLC analysis (top) and enzymatic activity of fractions 
collected during SEC-HPLC analysis (bottom) of pooled, purified 
preparations of pCocSH (inset). Monomer, dimer, and tetramer 
fractions are indicated with 1°, 2°, and 4° respectively. 
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 After concentration, 0.02% sodium azide (NaN3) was added to prevent unwanted 
organismal growth during storage which was subsequently dialyzed out against 3× 4 L 
PBS, pH 7.4 prior to use for animal experiments. Plant extractions for this preparation 
were originally conducted in May-June of 2013 and the final purified material was stored 
at 4°C until it was used for animal studies in February of 2015. No precipitation or 
turbidity of any kind was observed during storage. 
Purified Enzyme and Drug Preparation 
 The amount and concentration of pCocSH in final purified product was 
determined both based on enzymatic activity and absorbance of purified material at 
280nm using both a NanoDrop 2000 (Thermo Scientific) and DU 640 Spectrophotometer 
(Beckman Coulter). Analysis was conducted upon initial purification as well as 
immediately before animal studies were conducted (less than 12 hours prior). Serial 
dilutions of purified protein were prepared and absorbance was recorded as a wavelength 
scan over 200-300 nm and the absorbance at 280 nm was noted. Using this absorbance, 
the Beer-Lambert law was used to determine protein concentration (M) using the 
computationally determined extinction coefficient specific for pCocSH (ε =133,310 M-
1cm-1) and the concentration (M) was converted to mg/mL using the molecular weight of 
pCocSH based on its specific amino acid sequence (65956.7 Da/ L). The molecular 
weight and extinction coefficient were determined based on the amino acid sequence of 
pCocSH (assuming fully cleaved SP and 6x histidine tag) using the ProtParam tool from 
the Expert Protein Analysis System (ExPASy) Bioinformatics Resource Portal (Wilkins 
et al., 1999).  
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 The (-)-cocaine hydrolchloride (RTI International Triangle Park, NC, USA) was 
weighed then dissolved in sterile 0.9% saline and filtered through a 0.2 µm membrane. 
From this concentrated stock, serial dilutions were prepared in sterile 0.9% saline to the 
indicated concentrations.  
Animals 
 Black C57BL/6 male mice weighing approximately 25-30 g at the start of the 
experiment were housed 5 mice per cage with free access to food and water in a 
temperature-controlled colony room with a reversed 12-h light:dark cycle and allowed at 
least one week to acclimate upon arrival to the housing facility. All animal experiments 
were performed in accordance to protocol approved by the Institutional Care and Use 
Committee of Arizona State University. Length and number of convulsions were 
recorded. Moribund animals, and all animals by the end of the observation period were 
euthanized by CO2 asphyxiation followed by a secondary method of euthanasia (cervical 
dislocation). Moribundity was defined as prolonged seizures (120 s) or more than two 
shorter seizures within 2 minutes. 
Intravenous Enzyme and Intraperitoneal Drug Administration  
 For intravenous (i.v.) injections of highly purified pCocSH or vehicle control 
(PBS, pH 7.4), mice were placed in a commercial mouse restrainer. The exposed tail was 
cleaned with an alcohol wipe and a U-100 insulin syringe (28G1/2) needle (Becton 
Dickinson) was used for injection into one of the tail veins. The i.v. injection volume did 
not exceed 5 µL/g mouse.  
 Mice were released from the restraint as soon as the injection was complete and 
sterile gauze and pressure were applied to the injection site to stop any bleeding. Cocaine 
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or vehicle control (0.9% saline) was delivered intraperitoneally (i.p.) using the same kind 
of syringe as described above. Injection volume did not exceed 10 µL/g mouse. After 
injections, mice were placed in individual transparent polystyrene cages (1 mouse per 
cage) for observation. The presence or absence of convulsions, lethality, and general 
observations were recorded for 60 minutes after cocaine administration or, if applicable, 
until euthanasia criteria was met as described previously. 
Protection Experiment 
 The goal of the first study was to determine the ability of pCocSH to protect from 
cocaine-induced toxicity. In the protection study, vehicle control (1× PBS, pH 7.4) or 
purified pCocSH (3 or 10 mg/kg mouse) was administered i.v. (tail) 5 minutes before i.p. 
administration of the indicated doses of cocaine (Figure 35). We first determined the dose 
response to cocaine in absence of any protection using the following cocaine doses: 0, 30, 
55, 75 and 100 mg/kg). Higher doses of cocaine were needed to observe toxicity when 
pCocSH (3 or 10 mg/kg) was administered: 100, 180, 325, 585, and 1055 mg/kg. There 
were 6 animals per experimental group.  
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Figure 35. Timeline of protection experiment.  
pCocSH (3 or 10 mg/kg) or vehicle control was delivered (i.v.) 5 minutes prior 
to  the administration of varying doses of cocaine (i.p). Acute symptoms in 
control animals arose within the first 5 minutes following the cocaine 
challenge. Experiment was concluded 60 minutes post cocaine administration. 
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Rescue from Acute Cocaine Toxicity 
 For the rescue study, cocaine (100 mg/kg) was i.p. administered. Immediately 
upon the onset of cocaine-induced convulsions, mice were i.v. injected with pCocSH (3 
or 10 mg/kg mouse) or PBS control (Figure 36).  
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Figure 36. Timeline of rescue experiment.  
Cocaine (100 mg/kg) was administered (i.p.). pCocSH (3 or 10 mg/kg) or vehicle control 
was delivered (i.v.) within approximately 1 minute of the first cocaine-induced 
convulsions. Experiment was concluded 60 minutes post cocaine administration. 
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Statistical Analysis 
 Statistical analyses were carried out using the GraphPad Prism software. Log-rank 
(Mantel-Cox) test was used to determine significance of the difference between treatment 
and control group survival and recovery curves. Data from the behavioral toxicity studies 
(percentage of mice showing lethality) were analyzed with Fisher’s exact probability test 
with two tail). The criterion for significance was set at p < 0.05. 
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Results and Discussion 
The aim of this study was to provide proof-of-principle that pCocSH can protect 
mice from acute cocaine intoxication (overdose) when given prophylactically, and rescue 
mice from overdose of cocaine when given soon after onset of cocaine-induced seizures. 
To test this, two main studies were designed. The first was to determine the protective 
dose response for pCocSH while the second was to determine if post-exposure protection 
(rescue) from overdose could be afforded by pCocSH.  
Protection Study and Generation of Dose Response Curves 
 In order to test our hypothesis that pCocSH could protect animals from cocaine-
induced acute toxicity, we first conducted a protection study in mice. Animals were i.v. 
administered pCocSH (3 or 10 mg/kg) or vehicle control (PBS, pH 7.4) and challenged 
five minutes later with varying concentrations of cocaine (delivered i.p.). There were 6 
animals in each experimental group. The mammalian-derived enzyme was shown to be 
protective of a lethal 180 mg/kg dose of cocaine at a low enzyme dose of approximately 1 
mg/kg in mice when delivered 1 minute before cocaine administration (Zheng et al., 
2008; Xue et al., 2011). In a separate study, a dose-response curve for seizures was 
generated using a higher enzyme dose of 10 mg/kg in rats when given 10 minutes prior to 
cocaine administration (Brimijoin et al., 2008). We sought to administer the enzyme at 5 
minutes prior to cocaine administration and we wanted to determine if there was a dose-
dependent protection afforded by the enzyme; therefore, we chose to test both a low (3 
mg/kg) and high (10 mg/kg) enzyme dosing regimen for this study. 
 Administration of cocaine at 30 mg/kg (N = 6) following pre-treatment with 
vehicle, resulted mice displaying typical cocaine-induced hyper-locomotion, but no signs 
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of stress or acute toxicity. Mice challenged with higher doses of cocaine displayed dose-
dependent toxicity symptoms. At 55 mg/kg these symptoms were observed in one mouse 
out of 6 (16.7%). However, all mice (100%, N = 6) receiving a 75 mg/kg dose of cocaine 
exhibited cocaine-induced seizures. In four out of the 6 mice (67%), these symptoms 
were severe enough to consider the animals as moribund necessitating their euthanasia, 
while two mice recovered during the one-hour observation window. A higher cocaine 
dose (100 mg/kg) caused severe convulsions and moribundity in all tested mice (100%, N 
= 6). We therefore consider this dose to be LD100 for cocaine in black C57BL/6 mice. The 
apparent ED100 for convulsions and tremors based on this experiment was 75 mg/kg 
(Figure 37). In previously published work, Ko and coworkers (2007) reported slightly 
higher values for the somewhat distantly related outcrossed NIH-Swiss. Ko et al 
determined the LD100 values to be 130 mg/kg, however their observations are based on 
death as an endpoint, where we use the more subjective moribundity criteria outlined in 
the Materials and Method section.  
 To test the protective effects of pCocSH, the cocaine dose response curves were 
obtained in mice that were pre-treated with either a low (3 mg/kg) or a high (10 mg/kg) 
dose of the plant-derived enzyme. Mice that were pre-treated with the low dose of 
pCocSH were almost fully protected from a cocaine dose (100 mg/kg) that killed 100% 
of mice in the vehicle control group. In fact, only one mouse of the 6 challenged with this 
cocaine dose (1/6, 16.7%) showed signs of acute toxicity (Figure 37). This mouse seized 
for > 60 seconds and was subsequently euthanized. None of the other mice (5/6) had any 
seizures, tremors, or other signs of acute toxicity. At 585 mg/kg cocaine, all mice (100 
%) seized for > 60 seconds and were euthanized. 
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 Mice were then treated with a higher enzyme dose of 10 mg/kg. Mice given this 
treatment did not exhibit any signs of cocaine-induced seizures or tremors at 100 or 180 
mg/kg cocaine, which was 100% lethal in unprotected mice. At 180 mg/kg the mice 
initially had slightly decreased motor activity, which subsided within a few minutes. At 
353 mg/kg most mice began to show neurologic symptoms (dragging feet, dystaxia, 
knuckle walking) but only 1 mouse exhibited seizures. At an even higher dose of 585 
mg/kg, all mice (100%) exhibited neurologic symptoms described above as well as 
labored breathing and decreased locomotion. These mice had decreased responsiveness to 
stimuli, dyspnea, and decreased locomotion indicative of phase II acute cocaine toxicity 
rather than the premorbid phase III state. Therefore, even at doses nearly 20 fold higher 
than the typical rewarding cocaine dose of 30 mg/kg, animals are protected from 
advanced stages of acute cocaine toxicity. At this dose, 50% of the mice (3/6) recovered 
during the observation time and only three became moribund and had to be euthanized. 
With a protective pCocSH dose of 10 mg/kg, LD100 was reached only at 1055 mg/kg of 
cocaine, a >10 fold higher dose compared to unprotected control mice (Figure 37). This is 
equivalent to a mammalian (CHO cell) derived albumin-fused BChE variant’s 
(A199S/S287G/A328W/Y332G) ability to protect rats (Brimijoin et al., 2008) and to the 
effect of the bacterial derived cocaine esterase (CocE) enzyme to protect mice (Ko et al., 
2007) and rats (Cooper et al., 2006). 
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Figure 37. Protection of mice from cocaine-induced acute 
toxicity. 
Dose response curves of cocaine-induced convulsions and 
tremors (top) and lethality (bottom). Each data point 
represents the % of mice (N=6, unless otherwise noted) for 
each dosing condition. 
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Rescue Study 
 The protection experiment allowed us to determine the dose acute-toxicity 
responses to cocaine in protected and unprotected mice. To simulate a more clinically 
relevant scenario, we then turned to determine if pCocSH can still provide protection 
when delivered after cocaine-challenged subjects become symptomatic. To evaluate the 
potential for pCocSH to rescue mice from cocaine overdose, we i.p. injected mice with 
the LD100 dose of cocaine as determined in the previously describe experiment (100 
mg/kg). Immediately upon onset of convulsions, mice were treated by i.v. injection 
through the tail vein with either low dose (3 mg/kg), high dose (10 mg/kg) of pCocSH or 
vehicle control (Figure 36).  
 As expected, all of the mice challenged by cocaine experienced severe effects of 
cocaine toxicity, except for one mouse that displayed no severe symptoms and therefore 
was excluded from the study and was not considered further. The interval between 
cocaine administration and onset of convulsions was 4.8 ± 0.5 minutes (N = 17). One 
animal died while being restrained prior to receiving further treatment and was 
subsequently removed from the study.  
 The 100 mg/kg dose of cocaine was lethal to all 5 control (vehicle-treated) mice 
that exhibited cocaine-induced convulsions and were euthanized upon moribundity. 
Strikingly, all of the mice (N = 6) treated with 3 mg/kg pCocSH soon after the onset of 
seizures survived (Figure 38). In all pCocSH-treated subjects, convulsions ceased within 
1 minute of treatment. Thus, pCocSH can reverse the acute effects of cocaine-induced 
toxicity in mice when given soon after the onset of convulsions. Moreover, most mice 
(4/6, 66.7%) fully recovered by the end of the observation period with only two of the 
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mice (2/6, 33.3%) continuing to experience some mild symptoms. Delivery of the 
enzyme for these two mice took nearly 3 times longer than the other 4 mice. This 
prolonged time of seizing before receiving the full dose of the enzyme likely led to the 
lethargy observed in these mice. 
 Similar results of rescue were observed for mice (N = 5) treated with the high 
dose of pCocSH 10 mg/kg (Figure 38). All of these mice ceased convulsing in <1 minute 
(more precise time points were not recorded) and all mice resumed upright posture in <10 
minutes (Table 8, Figure 39). Mice that received the full 10 mg/kg dose of pCocSH after 
onset of convulsions induced by 100 mg/kg cocaine exhibited an extremely rapid return 
to a normal state. In the time it took to replace the animal in its cage (< 30 seconds), the 
mouse began to walk normally and resume normal behavior. In future studies it would be 
interesting to examine how late one could receive pCocSH and still be rescued in order to 
more closely simulate an emergency department scenario. A different animal model must 
be used for such studies however, as the convulsion-to-death interval in mice has been 
shown to be very short (1.5 minutes in NIH-Swiss mice) (Ko et al., 2007) and an ideal 
animal model with sufficiently long convulsion-death interval is not currently known.  
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Figure 38. Rescue from acute symptoms of cocaine toxicity with pCocSH.  
Symptom severity displayed by each mouse at the end of the 60 minute experiment 
is shown. Symptom score was 0, asymptomatic; 1, decreased motor activity; 2, 
tremors or fasciculation; 3, convulsions; 4, death. Individual mice (represented by 
symbols) were i.p. injected with cocaine in saline (100 mg⁄kg). Upon onset of 
cocaine-induced seizures, pCocSH (3 or 10 mg/kg) or vehicle control was delivered 
i.v and animals were observed for 60 minutes. Each data point represents the 
percent of mice for each dosing condition exhibiting lethality. The asterisks 
represent a significant difference from the condition of mice treated with PBS (* p 
< 0.05, ** p < 0.01). See Materials and Methods for details. 
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Table 8. pCocSH rescues from cocaine overdose 
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 Mice receiving a complete dose of 10 mg/kg pCocSH all ceased convulsing and 
resumed upright posture with no signs of toxicity in less than one minute (Table 8, Figure 
39). One mouse did not receive the complete dose of 10 mg/kg pCocSH due to some 
leaking back out of the injection site. Interestingly, this mouse also had a correspondingly 
longer time to regain upright posture (Table 8), similar to the lower 3 mg/kg enzyme 
dose. The previously described mouse which died likely from cocaine-induced heart 
failure was included in analysis determining the time until upright posture was resumed 
(Figure 39) following enzyme treatment; however, it is not a true indication of the ability 
of pCocSH (10 mg/kg) to rescue from cocaine overdose in this mouse because the mouse 
died before the complete dose could even be injected. In both the low and high enzyme 
groups, 67% of the mice regained upright posture in 1 minute or less following enzyme 
treatment, compared to 0% of the mice in the control group (Figure 39). All (100%) of 
the mice treated with complete doses of pCocSH (entire 3 or 10 mg/kg) which had 
exhibited cocaine-induced seizures were saved from subsequent death compared to 0% of 
mice which seized and received vehicle control. 
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Figure 39. Time to recovery from cocaine-induced seizures following pCocSH treatment. 
Effects of pCocSH in reversing cocaine-induced acute toxicity. Time (in minutes) from 
the onset of cocaine-induced convulsions until upright posture and normal motor activity 
resumed is shown. Comparison by the Log-rank (Mantel-Cox) test between low dose and 
control (p = 0.001) and high dose and control (p= 0.0016) were significant. 
 
   
  
  
157 
 Our results provide the proof-of-principle that the plant-derived enzyme, pCocSH, 
can rescue animals from cocaine overdose when given soon after the onset of cocaine-
induced convulsions. Although tetrameric pCocSH is not more potent than the 
monomeric form, it is more stable in circulation, and it will be interesting to test the 
difference in pharmacokinetics between the tetrameric and monomeric forms of pCocSH. 
Future studies will aim to test the hypothesis that pCocSH can prevent reinstatement of 
extinguished drug-seeking behavior in mice that were conditioned to cocaine. This work 
demonstrates, for the first time, the application of recombinant BChE-based cocaine 
hydrolase variants produced in plants as a successful treatment for cocaine overdose. 
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6 SUMMARY AND OUTLOOK 
 Cocaine abuse is a global problem with major medical and societal consequences. 
Despite this, patients suffering from acute toxicity (overdose) are only symptomatically 
treated and there is no FDA-approved treatment to decrease the likelihood of relapse in 
rehabilitated addicts. Developing a treatment for cocaine overdose and addiction, 
however, is not an easy task. Classic strategies using a pharmacodynamics approach have 
attempted to utilize small molecules to counteract the actions of the drug using 
medications that are agonists and/or antagonists of cocaine with little success (Zheng and 
Zhan, 2011). It is difficult to block the action of cocaine without also having undesirable 
consequences within the central nervous system. This led to the development of a 
strategy aimed at breaking down the drug itself (Gorelick, 2012).  
 Therapeutic enzymes quickly became a focus for a potential anti-cocaine 
treatment. Butyrylcholinesterase (BChE) is the primary cocaine-metabolizing enzyme in 
human serum (Lynch et al., 1997; Lockridge, 2015). Wild type (WT) BChE has a wide 
substrate specificity, especially in comparison to the highly specific homologous enzyme 
acetylcholinesterase. BChE may play a role as a generalized bioscavenger, binding or 
hydrolyzing various xenobiotic agents and toxicants, many of which target the central 
and peripheral nervous systems (Lockridge et al., 2011). It is in this sense that it also 
detoxifies cocaine. Although the enzyme has a wide substrate specificity, it is not very 
efficient at hydrolyzing cocaine. It can clear cocaine over time; however a high bolus of 
cocaine would easily overwhelm the endogenous enzyme. The goal of a 
pharmacokinetic-based therapy would be to rapidly decrease the concentration of cocaine 
by quickly breaking the drug down into pharmacologically inactive metabolites. To this 
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end, computational strategies have been developed to design BChE mutants with 
improved catalytic activity against cocaine (Pan et al., 2005; Gao et al., 2006; Zheng et 
al., 2008). This led to the discovery of high activity cocaine hydrolase BChE mutants 
including the most promising variant (pCocSH, A199S/F227A/S287G/A328W/Y332G) 
with approximately 2000 fold higher catalytic efficiency compared to WT BChE (Zheng 
et al., 2008; Xue et al., 2013a). These studies by the Chang-Guo Zhan group have shown 
the great potential of these computationally-designed cocaine hydrolase variants of 
BChE. A shortcoming needing to be addressed is that current mammalian-based 
expression systems being used to produce these enzymes are neither easily scalable nor 
cost-effective. To be an effective treatment for the millions of people affected by drug 
addiction and overdose, the enzyme-based therapy necessitates large quantities of the 
protein that are not prohibitively expensive. 
 To address this need, we set out to produce variants of BChE designed for 
enhanced cocaine hydrolysis, particularly pCocSH, in plants. By using plants as a source 
for these human biologics, we hope to contribute toward the development of a 
sustainable, inexpensive production system for this enzyme-based anti-cocaine treatment. 
Over the past decade, the Mor lab has pioneered the use of plants as an expression system 
for BChE and mutants thereof (Geyer et al., 2005; Evron et al., 2007; Geyer et al., 2007; 
Geyer et al., 2008; Geyer et al., 2010a; Geyer et al., 2010b; Geyer et al., 2013). Plant 
expression of the pCocSH variant of BChE has never before been tested. I was able to 
successfully express all cocaine hydrolase variants of interest in the tobacco relative, 
Nicotiana benthamiana. Although multiple variants are described in this study, I will 
focus this discussion on pCocSH, the most clinically relevant variant. I was able to create 
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two separate stable transgenic plant lines. One stable transgenic line expresses pCocSH 
targeted to the secretory pathway and another stable line expresses a variant of pCocSH 
designed to be retained in the endoplasmic reticulum. These stable transgenic lines 
accumulated substantial amounts of the tetrameric form of BChE - a desirable form for its 
improved pharmacokinetic properties. Using a transient tobacco mosaic virus-based 
expression system I was also able to produce pCocSH at quantities relevant to clinic use, 
reaching accumulation levels higher than any previously reported plant-derived BChE. 
Furthermore, I was able to improve upon this transient system that primarily produces 
BChE as monomers and dimers. Increasing the proportion of tetrameric BChE was 
achieved by co-expressing the peptide rQ45 derived from the N-terminus of the collagen-
tail protein. In conjunction with previous reports in mammalian-based expression systems 
(Altamirano and Lockridge, 1999a; Duysen et al., 2002), we showed that the co-
expression of rQ45 results in an increase in the higher oligomeric forms of the enzyme. 
The co-expression of these two proteins in plants was made possible by the creation of 
versatile vector systems developed in the laboratory of Dr. Hugh Mason that are based on 
the genetic elements of the bean yellow dwarf virus. Tetrameric recombinant BChE is 
sought after due to the increased circulatory half-life associated with tetramers. This will 
be our next area of focus. We will take these studies to an animal model in order to 
determine the pharmacokinetic parameters of the various oligomeric forms of pCocSH. 
Glycan structure can also play a role in circulatory stability of recombinant proteins and 
this will be a complimentary path of future study to determine if the glycan moieties on 
pCocSH are similar to those on plant-derived WT BChE. Furthermore, it should be 
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investigated if, like WT pBChE, pCocSH can be expressed with an engineered 
glycosylation profile similar to the more stable, native plasma-derived enzyme.  
 In addition to expressing pCocSH in plants, I biochemically characterized the 
bioscavenging properties of pCocSH. Enhanced affinity of BChE toward 
anticholinesterase agents is extremely relevant to the development of BChE-based nerve 
agent bioscavengers. We found that not only is pCocSH able to hydrolyze its target 
substrate, cocaine, but in addition it can bind various anti-cholinesterase agents with a 
higher binding affinity compared to WT BChE. These studies demonstrate the potential 
for these cocaine hydrolase variants to function as a multivalent antidote for both cocaine 
and anticholinesterase poisoning. 
 First I determined that plants can serve as a source for pCocSH and that the plant-
derived enzyme displayed kinetics in vitro similar to mammalian-derived cocaine 
hydrolases. The next step was to test the enzyme in an animal model for its ability to 
protect mice from cocaine overdose and reverse cocaine-induced toxicity. The goal of the 
first study was to determine the ability of pCocSH to protect mice from cocaine-induced 
toxicity when administered i.v. 5 minutes before i.p. administration of cocaine. I show 
that a protective dose of 10 mg/kg pCocSH causes 10 fold rightward shift in the dose 
response to cocaine compared to unprotected mice. Strikingly, all mice protected with 10 
mg/kg pCocSH demonstrated no signs of acute toxicity when administered an otherwise 
lethal dose (LD100) of cocaine. 
 The protection experiment allowed us to confirm the function of our plant-derived 
enzyme in vivo and determine the overdose responses to cocaine in protected and 
unprotected mice. To simulate a more clinically relevant scenario, we then conducted a 
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rescue experiment in which pCocSH was delivered after cocaine-challenged mice 
exhibited cocaine-induced seizures. To evaluate the potential for pCocSH to rescue mice 
from cocaine overdose, we i.p. injected mice with the LD100 dose of cocaine then 
immediately upon onset of convulsions, treated the mice by i.v. injection with either low 
or high dose of pCocSH or vehicle control 
 Through these studies it was revealed that pCocSH administered at levels as low 
as 3 mg/kg can fully protect mice from an otherwise lethal dose (LD100) of cocaine from 
subsequent death, and rapidly reverse toxicity symptoms. All of the mice treated with 
pCocSH ceased convulsing in <1 minute and all mice resumed upright posture in less 
than 10 minutes. Mice that received the full 10 mg/kg dose of pCocSH after onset of 
convulsions induced by a lethal dose of cocaine nearly instantaneously returned to a 
normal state.  
 Our results provide the proof-of-principle that the plant-derived enzyme, pCocSH, 
can rescue animals from cocaine overdose when given soon after the onset of cocaine-
induced convulsions. This work demonstrates, for the first time, the application of 
recombinant BChE-based cocaine hydrolase variants produced in plants as a successful 
treatment for cocaine overdose.  
 Based on these exciting findings, our next goal is to test our hypothesis that 
pCocSH can prevent reinstatement of extinguished drug-seeking behavior in mice that 
were conditioned to cocaine. To test this, mice will be conditioned to cocaine and the 
effect of pCocSH on the expression of cocaine-induced conditioned place preference 
directly and after a 14-day extinction phase will be tested. There is currently no FDA-
approved treatment to decrease the likelihood of relapse in rehabilitated addicts and we 
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hope to provide an in vivo proof-of-principle for a promising plant-derived human 
biologic that I developed and extensively analyzed in our lab. 
 This work is the first successful demonstration of the use of a plant-based 
expression platform for the production of recombinant BChE-based cocaine hydrolase 
variants. In addition to this success, the plant-derived enzyme pCocSH served as 
successful treatment for cocaine overdose. This work demonstrates the ability of plants to 
serve as a sustainable, scalable, affordable platform for the production of 
pharmaceutically relevant human biologics. I hope that our exciting results and future 
endeavors will lead to the development a cost-effective, safe, plant-based expression 
platform to produce therapeutics that will one day be used as an affordable, effective 
treatment of cocaine overdose and addiction. 
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